The	O
ability	O
of	O
BHRF1	B-protein
to	O
inhibit	O
apoptosis	O
is	O
dependent	O
on	O
stimulus	O
and	O
cell	O
type	O
.	O

The	O
development	O
of	O
resistance	O
to	O
host	O
defense	O
mechanisms	O
such	O
as	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
and	O
Fas-mediated	O
apoptosis	O
of	O
transformed	B-cell_type
or	O
virus-infected	B-cell_type
cells	I-cell_type
may	O
be	O
a	O
critical	O
component	O
in	O
the	O
development	O
of	O
disease	O
.	O

To	O
find	O
genes	O
that	O
protect	O
cells	O
from	O
apoptosis	O
,	O
we	O
used	O
an	O
expression	O
cloning	O
strategy	O
and	O
identified	O
BHRF1	B-protein
,	O
an	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
early-lytic-cycle	I-protein
protein	I-protein
with	O
distant	O
homology	O
to	O
Bcl-2	B-protein
,	O
as	O
an	O
anti-apoptosis	B-protein
protein	I-protein
.	O

Expression	O
of	O
BHRF1	B-protein
in	O
MCF-Fas	B-cell_line
cells	I-cell_line
conferred	O
nearly	O
complete	O
resistance	O
against	O
both	O
anti-Fas	B-protein
antibody	I-protein
and	O
TNF-mediated	O
apoptosis	O
.	O

In	O
addition	O
,	O
BHRF1	B-protein
protected	O
these	O
cells	O
from	O
monocyte-mediated	O
killing	O
but	O
failed	O
to	O
protect	O
them	O
from	O
killing	O
mediated	O
by	O
lymphokine-activated	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

The	O
ability	O
of	O
BHRF1	B-protein
to	O
protect	O
MCF-Fas	B-cell_line
cells	I-cell_line
from	O
apoptosis	O
induced	O
by	O
various	O
stimuli	O
was	O
identical	O
to	O
that	O
of	O
Bcl-2	B-protein
and	O
Bcl-xL	B-protein
.	O

Moreover	O
,	O
the	O
mechanism	O
of	O
action	O
of	O
BHRF1	B-protein
resembled	O
that	O
of	O
Bcl-2	B-protein
and	O
Bcl-xL	B-protein
as	O
it	O
inhibited	O
TNF-	O
and	O
anti-Fas-induced	O
activation	O
of	O
two	O
enzymes	O
participating	O
in	O
the	O
apoptosis	O
pathway	O
,	O
cytosolic	B-protein
phospholipase	I-protein
A2	I-protein
and	O
caspase-3/CPP32	B-protein
,	O
but	O
did	O
not	O
interfere	O
with	O
the	O
activation	O
of	O
NF-kappaB-like	B-protein
transcription	I-protein
factors	I-protein
.	O

A	O
putative	O
function	O
of	O
BHRF1	B-protein
in	O
EBV-infected	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
may	O
be	O
to	O
protect	O
virus-infected	O
cells	O
from	O
TNF-	O
and/or	O
anti-Fas-	O
induced	O
cell	O
death	O
in	O
order	O
to	O
maximize	O
virus	O
production	O
.	O

Surprisingly	O
,	O
expression	O
of	O
neither	O
BHRF1	B-protein
nor	O
Bcl-2	B-protein
in	O
a	O
B-cell	B-cell_line
line	I-cell_line
,	O
BJAB	B-cell_line
,	O
protected	O
the	O
cells	O
from	O
anti-Fas-mediated	O
apoptosis	O
even	O
though	O
they	O
increased	O
the	O
survival	O
of	O
serum-starved	B-cell_type
cells	I-cell_type
.	O

Thus	O
,	O
the	O
protective	O
role	O
of	O
BHRF1	B-protein
against	O
apoptosis	O
resembles	O
that	O
of	O
Bcl-2	B-protein
in	O
being	O
cell	O
type	O
specific	O
and	O
dependent	O
on	O
the	O
apoptotic	O
stimulus	O
.	O

JouRrnaL	NULL
or	NULL
Oct.	NULL
1997	NULL
,	NULL
p.	NULL
7509-7517	NULL
0022-538X/97/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1997	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

71	NULL
,	NULL
No	NULL
.	NULL

10	NULL
The	NULL
Ability	NULL
of	NULL
BHRF1	NULL
To	NULL
Inhibit	NULL
Apoptosis	NULL
Is	NULL
Dependent	NULL
on	NULL
Stimulus	NULL
and	NULL
Cell	NULL
Type	NULL
LASSE	NULL
FOGHSGAARD	NULL
anp	NULL
MARJA	NULL
JAATTELA*	NULL
Apoptosis	NULL
Laboratory	NULL
,	NULL
Division	NULL
for	NULL
Cancer	NULL
Biology	NULL
,	NULL
Danish	NULL
Cancer	NULL
Society	NULL
,	NULL
DK-2100	NULL
Copenhagen	NULL
,	NULL
Denmark	NULL
Received	NULL
14	NULL
May	NULL
1997/Accepted	NULL
16	NULL
July	NULL
1997	NULL
The	NULL
development	NULL
of	NULL
resistance	NULL
to	NULL
host	NULL
defense	NULL
mechanisms	NULL
such	NULL
as	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
-	NULL
and	NULL
Fas-mediated	NULL
apoptosis	NULL
of	NULL
transformed	NULL
or	NULL
virus-infected	NULL
cells	NULL
may	NULL
be	NULL
a	NULL
critical	NULL
component	NULL
in	NULL
the	NULL
development	NULL
of	NULL
disease	NULL
.	NULL

To	NULL
find	NULL
genes	NULL
that	NULL
protect	NULL
cells	NULL
from	NULL
apoptosis	NULL
,	NULL
we	NULL
used	NULL
an	NULL
expression	NULL
cloning	NULL
strategy	NULL
and	NULL
identified	NULL
BHRF1	NULL
,	NULL
an	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
early-lytic-cycle	NULL
protein	NULL
with	NULL
distant	NULL
homology	NULL
to	NULL
Bcl-2	NULL
,	NULL
as	NULL
an	NULL
antiapoptosis	NULL
protein	NULL
.	NULL

Expression	NULL
of	NULL
BHRF1	NULL
in	NULL
MCF-Fas	NULL
cells	NULL
conferred	NULL
nearly	NULL
complete	NULL
resistance	NULL
against	NULL
both	NULL
anti-Fas	NULL
antibody	NULL
and	NULL
TNF-mediated	NULL
apoptosis	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
BHRF1	NULL
protected	NULL
these	NULL
cells	NULL
from	NULL
monocyte-mediated	NULL
killing	NULL
but	NULL
failed	NULL
to	NULL
protect	NULL
them	NULL
from	NULL
killing	NULL
mediated	NULL
by	NULL
lymphokine-activated	NULL
killer	NULL
cells	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
BHRF1	NULL
to	NULL
protect	NULL
MCF-Fas	NULL
cells	NULL
from	NULL
apoptosis	NULL
induced	NULL
by	NULL
various	NULL
stimuli	NULL
was	NULL
identical	NULL
to	NULL
that	NULL
of	NULL
Bel-2	NULL
and	NULL
Bcel-x	NULL
,	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
BHRF1	NULL
resembled	NULL
that	NULL
of	NULL
Bel-2	NULL
and	NULL
Bel-x	NULL
,	NULL
,	NULL
as	NULL
it	NULL
inhibited	NULL
TNF-	NULL
and	NULL
anti-Fas-induced	NULL
activation	NULL
of	NULL
two	NULL
enzymes	NULL
participating	NULL
in	NULL
the	NULL
apoptosis	NULL
pathway	NULL
,	NULL
cytosolic	NULL
phospholipase	NULL
A	NULL
,	NULL
and	NULL
caspase-3/CPP32	NULL
,	NULL
but	NULL
did	NULL
not	NULL
interfere	NULL
with	NULL
the	NULL
activation	NULL
of	NULL
NF-B-like	NULL
transcription	NULL
factors	NULL
.	NULL

A	NULL
putative	NULL
function	NULL
of	NULL
BHRF1	NULL
in	NULL
EBV-infected	NULL
epithelial	NULL
cells	NULL
may	NULL
be	NULL
to	NULL
protect	NULL
virus-infected	NULL
cells	NULL
from	NULL
TNF-	NULL
and/or	NULL
anti-Fas-induced	NULL
cell	NULL
death	NULL
in	NULL
order	NULL
to	NULL
maximize	NULL
virus	NULL
production	NULL
.	NULL

Surprisingly	NULL
,	NULL
expression	NULL
of	NULL
neither	NULL
BHRF1	NULL
nor	NULL
Bel-2	NULL
in	NULL
a	NULL
B-cell	NULL
line	NULL
,	NULL
BJAB	NULL
,	NULL
protected	NULL
the	NULL
cells	NULL
from	NULL
anti-Fas-mediated	NULL
apoptosis	NULL
even	NULL
though	NULL
they	NULL
increased	NULL
the	NULL
survival	NULL
of	NULL
serum-starved	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
protective	NULL
role	NULL
of	NULL
BHRF1	NULL
against	NULL
apoptosis	NULL
resembles	NULL
that	NULL
of	NULL
Bcl-2	NULL
in	NULL
being	NULL
cell	NULL
type	NULL
specific	NULL
and	NULL
dependent	NULL
on	NULL
the	NULL
apoptotic	NULL
stimulus	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
is	NULL
a	NULL
multifunctional	NULL
cytokine	NULL
capable	NULL
of	NULL
inducing	NULL
apoptosis	NULL
in	NULL
a	NULL
number	NULL
of	NULL
transformed	NULL
or	NULL
virus-infected	NULL
cells	NULL
(	NULL
10	NULL
,	NULL
18	NULL
,	NULL
44	NULL
)	NULL
.	NULL

The	NULL
pleiotropic	NULL
effects	NULL
of	NULL
TNF	NULL
are	NULL
mediated	NULL
by	NULL
two	NULL
distinct	NULL
but	NULL
structurally	NULL
related	NULL
cell	NULL
surface	NULL
receptors	NULL
,	NULL
TNF-R1	NULL
and	NULL
TNF-R2	NULL
(	NULL
47	NULL
,	NULL
51	NULL
)	NULL
.	NULL

TNF	NULL
receptors	NULL
are	NULL
members	NULL
of	NULL
a	NULL
larger	NULL
family	NULL
of	NULL
related	NULL
membrane	NULL
proteins	NULL
which	NULL
are	NULL
defined	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
extracellular	NULL
cysteine-rich	NULL
repeats	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Two	NULL
members	NULL
of	NULL
this	NULL
so-called	NULL
TNF	NULL
receptor	NULL
superfamily	NULL
,	NULL
TNF-R1	NULL
and	NULL
Fas	NULL
(	NULL
APO1/CD95	NULL
)	NULL
,	NULL
also	NULL
share	NULL
a	NULL
region	NULL
of	NULL
intracellular	NULL
homology	NULL
designated	NULL
the	NULL
``	NULL
death	NULL
domain	NULL
``	NULL
(	NULL
15	NULL
,	NULL
46	NULL
)	NULL
.	NULL

This	NULL
domain	NULL
is	NULL
an	NULL
essential	NULL
component	NULL
of	NULL
the	NULL
signal	NULL
pathway	NULL
that	NULL
triggers	NULL
apoptosis	NULL
.	NULL

Fas	NULL
ligand	NULL
(	NULL
FasL	NULL
)	NULL
is	NULL
expressed	NULL
predominantly	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
and	NULL
shows	NULL
strong	NULL
cytotoxic	NULL
activity	NULL
against	NULL
Fas-expressing	NULL
cells	NULL
(	NULL
43	NULL
)	NULL
.	NULL

FasL	NULL
,	NULL
like	NULL
TNF	NULL
,	NULL
has	NULL
antiviral	NULL
activity	NULL
and	NULL
is	NULL
also	NULL
involved	NULL
in	NULL
the	NULL
downregulation	NULL
of	NULL
immune	NULL
responses	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Like	NULL
other	NULL
apoptotic	NULL
stimuli	NULL
,	NULL
signaling	NULL
from	NULL
TNF	NULL
and	NULL
FasL	NULL
converges	NULL
into	NULL
a	NULL
common	NULL
cell	NULL
death	NULL
pathway	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
30	NULL
)	NULL
.	NULL

This	NULL
common	NULL
pathway	NULL
is	NULL
tightly	NULL
regulated	NULL
by	NULL
intracellular	NULL
decision	NULL
points	NULL
(	NULL
34	NULL
)	NULL
.	NULL

One	NULL
is	NULL
constituted	NULL
by	NULL
the	NULL
Bcl-2	NULL
family	NULL
of	NULL
proteins	NULL
,	NULL
which	NULL
is	NULL
comprised	NULL
of	NULL
positive	NULL
and	NULL
negative	NULL
regulators	NULL
of	NULL
cell	NULL
death	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
57	NULL
)	NULL
.	NULL

The	NULL
different	NULL
members	NULL
share	NULL
three	NULL
Bel-2	NULL
homology	NULL
domains	NULL
(	NULL
BH1	NULL
,	NULL
BH2	NULL
,	NULL
and	NULL
BH3	NULL
)	NULL
which	NULL
enable	NULL
the	NULL
proteins	NULL
to	NULL
homo-	NULL
or	NULL
heterodimerize	NULL
,	NULL
and	NULL
the	NULL
ratio	NULL
of	NULL
death	NULL
antagonists	NULL
(	NULL
Bel-2	NULL
,	NULL
Bel-x	NULL
,	NULL
,	NULL
Mecl-1	NULL
,	NULL
and	NULL
A1	NULL
)	NULL
to	NULL
death	NULL
agonists	NULL
(	NULL
Bax	NULL
,	NULL
Bak	NULL
,	NULL
Bel-xg	NULL
,	NULL
and	NULL
Bad	NULL
)	NULL
dictates	NULL
whether	NULL
a	NULL
cell	NULL
will	NULL
respond	NULL
to	NULL
apoptotic	NULL
stimuli	NULL
(	NULL
57	NULL
)	NULL
.	NULL

The	NULL
new	NULL
and	NULL
growing	NULL
family	NULL
of	NULL
caspases	NULL
,	NULL
cysteine	NULL
proteases	NULL
related	NULL
to	NULL
interleukin-1B-converting	NULL
enzyme	NULL
(	NULL
ICE/caspase-1	NULL
)	NULL
,	NULL
are	NULL
activated	NULL
in	NULL
apoptosis	NULL
and	NULL
are	NULL
now	NULL
recognized	NULL
as	NULL
major	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Apoptosis	NULL
Laboratory	NULL
,	NULL
Division	NULL
for	NULL
Cancer	NULL
Biology	NULL
,	NULL
Danish	NULL
Cancer	NULL
Society	NULL
,	NULL
Strandboule-varden	NULL
49	NULL
,	NULL
DK-2100	NULL
Copenhagen	NULL
,	NULL
Denmark	NULL
.	NULL

Phone	NULL
:	NULL
45-35257318	NULL
.	NULL

Fax	NULL
:	NULL
45-35257721	NULL
.	NULL

E-mail	NULL
:	NULL
mhji	NULL
@	NULL
biobase.dk	NULL
.	NULL

7509	NULL
effectors	NULL
of	NULL
apoptotic	NULL
cell	NULL
death	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
33	NULL
)	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
caspases	NULL
in	NULL
TNF-	NULL
and	NULL
Fas-mediated	NULL
apoptosis	NULL
has	NULL
been	NULL
clearly	NULL
demonstrated	NULL
by	NULL
studies	NULL
showing	NULL
that	NULL
(	NULL
i	NULL
)	NULL
receptor	NULL
activation	NULL
leads	NULL
to	NULL
proteolytic	NULL
activation	NULL
of	NULL
at	NULL
least	NULL
three	NULL
family	NULL
members	NULL
,	NULL
FLICE/MACH/caspase-8	NULL
,	NULL
CPP32/	NULL
caspase-3	NULL
,	NULL
and	NULL
ICE-LAP3/caspase-7	NULL
(	NULL
8	NULL
,	NULL
29	NULL
,	NULL
37	NULL
)	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
inhibitors	NULL
of	NULL
caspases	NULL
effectively	NULL
block	NULL
TNF-	NULL
and	NULL
Fas-mediated	NULL
apoptosis	NULL
(	NULL
9	NULL
,	NULL
24	NULL
,	NULL
48	NULL
)	NULL
;	NULL
and	NULL
finally	NULL
,	NULL
(	NULL
iii	NULL
)	NULL
ectopic	NULL
expression	NULL
of	NULL
caspases	NULL
in	NULL
several	NULL
cells	NULL
results	NULL
in	NULL
apoptosis	NULL
(	NULL
27	NULL
,	NULL
55	NULL
,	NULL
59	NULL
)	NULL
.	NULL

One	NULL
of	NULL
the	NULL
sub-strates	NULL
for	NULL
caspases	NULL
is	NULL
poly	NULL
(	NULL
ADP-ribose	NULL
)	NULL
polymerase	NULL
(	NULL
PARP	NULL
)	NULL
,	NULL
which	NULL
is	NULL
involved	NULL
in	NULL
DNA	NULL
repair	NULL
(	NULL
49	NULL
)	NULL
.	NULL

It	NULL
is	NULL
cleaved	NULL
and	NULL
inac-tivated	NULL
by	NULL
CPP32/caspase-3	NULL
during	NULL
apoptosis	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
TNF	NULL
was	NULL
shown	NULL
to	NULL
induce	NULL
caspase-dependent	NULL
cleavage	NULL
and	NULL
activation	NULL
of	NULL
cytosolic	NULL
phospholipase	NULL
A	NULL
;	NULL
,	NULL
(	NULL
cPLA	NULL
,	NULL
)	NULL
(	NULL
58	NULL
)	NULL
.	NULL

As	NULL
inhibitors	NULL
of	NULL
cPLA	NULL
,	NULL
partially	NULL
inhibit	NULL
TNF-induced	NULL
apoptosis	NULL
without	NULL
inhibition	NULL
of	NULL
caspase	NULL
activity	NULL
,	NULL
cPLA	NULL
,	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
a	NULL
mediator	NULL
of	NULL
TNF-induced	NULL
cell	NULL
death	NULL
acting	NULL
downstream	NULL
of	NULL
the	NULL
caspases	NULL
(	NULL
58	NULL
)	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
cPLA	NULL
;	NULL
has	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
crucial	NULL
for	NULL
TNF-induced	NULL
lysis	NULL
of	NULL
adenovirus-infected	NULL
cells	NULL
(	NULL
52	NULL
)	NULL
.	NULL

Viruses	NULL
have	NULL
evolved	NULL
different	NULL
strategies	NULL
affecting	NULL
different	NULL
parts	NULL
of	NULL
the	NULL
apoptotic	NULL
pathway	NULL
in	NULL
order	NULL
to	NULL
avoid	NULL
apoptosis	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
38	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
establishment	NULL
of	NULL
an	NULL
effective	NULL
adenoviral	NULL
infection	NULL
depends	NULL
on	NULL
the	NULL
function	NULL
of	NULL
the	NULL
19-kDa	NULL
E1B	NULL
protein	NULL
,	NULL
which	NULL
shows	NULL
distant	NULL
homology	NULL
to	NULL
Bel-2	NULL
and	NULL
is	NULL
able	NULL
to	NULL
protect	NULL
cells	NULL
from	NULL
TNF-	NULL
and	NULL
Fas-mediated	NULL
apoptosis	NULL
(	NULL
56	NULL
)	NULL
.	NULL

Other	NULL
examples	NULL
are	NULL
the	NULL
p35	NULL
protein	NULL
of	NULL
baculovirus	NULL
and	NULL
CrmA	NULL
of	NULL
cowpox	NULL
virus	NULL
,	NULL
which	NULL
are	NULL
able	NULL
to	NULL
bind	NULL
and	NULL
inhibit	NULL
multiple	NULL
members	NULL
of	NULL
the	NULL
caspase	NULL
family	NULL
and	NULL
thereby	NULL
to	NULL
prevent	NULL
apoptosis	NULL
induced	NULL
by	NULL
various	NULL
stimuli	NULL
(	NULL
3	NULL
,	NULL
4	NULL
,	NULL
9	NULL
,	NULL
48	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
using	NULL
a	NULL
cDNA	NULL
expression	NULL
cloning	NULL
strategy	NULL
,	NULL
we	NULL
have	NULL
identified	NULL
BHRF1	NULL
,	NULL
an	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
early	NULL
lytic	NULL
protein	NULL
with	NULL
sequence	NULL
homology	NULL
to	NULL
Bcel-2	NULL
,	NULL
as	NULL
an	NULL
antiapoptosis	NULL
protein	NULL
.	NULL

Expression	NULL
of	NULL
BHRF1	NULL
in	NULL
MCF-Fas	NULL
cells	NULL
renders	NULL
them	NULL
nearly	NULL
completely	NULL
resistant	NULL
against	NULL
both	NULL
anti-Fas-and	NULL
TNF-mediated	NULL
apoptosis	NULL
.	NULL

However	NULL
,	NULL
our	NULL
data	NULL
also	NULL
show	NULL
that	NULL
expression	NULL
of	NULL
BHRFI	NULL
in	NULL
a	NULL
B-cell	NULL
line	NULL
,	NULL
BJAB	NULL
,	NULL
does	NULL
not	NULL
7510	NULL
FOGHSGAARD	NULL
AND	NULL
JAATTELA	NULL
protect	NULL
them	NULL
from	NULL
anti-Fas-mediated	NULL
apoptosis	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
protective	NULL
role	NULL
of	NULL
BHRF1	NULL
is	NULL
cell	NULL
type	NULL
dependent	NULL
,	NULL
like	NULL
that	NULL
of	NULL
Bel-2	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
show	NULL
that	NULL
the	NULL
TNF-	NULL
and	NULL
anti-Fas-induced	NULL
activation	NULL
of	NULL
cPLA	NULL
;	NULL
and	NULL
caspase-3/CPP32	NULL
is	NULL
inhibited	NULL
in	NULL
BHRF1-expressing	NULL
MCF-Fas	NULL
cells	NULL
,	NULL
whereas	NULL
TNF-induced	NULL
NF-	NULL
«	NULL
B-activation	NULL
is	NULL
not	NULL
affected	NULL
.	NULL

A	NULL
putative	NULL
role	NULL
of	NULL
BHRF1	NULL
in	NULL
virus	NULL
infection	NULL
is	NULL
discussed	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
lines	NULL
,	NULL
culture	NULL
conditions	NULL
,	NULL
and	NULL
treatments	NULL
.	NULL

The	NULL
MCF7S1	NULL
cell	NULL
line	NULL
is	NULL
a	NULL
subclone	NULL
of	NULL
MCF7S	NULL
breast	NULL
carcinoma	NULL
cells	NULL
selected	NULL
by	NULL
limiting	NULL
dilution	NULL
of	NULL
MCF7S	NULL
cells	NULL
for	NULL
high	NULL
sensitivity	NULL
to	NULL
recombinant	NULL
human	NULL
TNF	NULL
(	NULL
17	NULL
)	NULL
.	NULL

The	NULL
Fas-sensitive	NULL
MCF-Fas	NULL
subclone	NULL
was	NULL
obtained	NULL
by	NULL
transfecting	NULL
a	NULL
Fas	NULL
receptor	NULL
expression	NULL
construct	NULL
into	NULL
the	NULL
MCF7S	NULL
cells	NULL
(	NULL
17	NULL
)	NULL
.	NULL

MCF-Bel-2.1	NULL
and	NULL
MCF-Bcl-2.2	NULL
are	NULL
two	NULL
pooled	NULL
populations	NULL
of	NULL
MCF-Fas	NULL
cells	NULL
successfully	NULL
transfected	NULL
with	NULL
a	NULL
pEBS7	NULL
expression	NULL
construct	NULL
coding	NULL
for	NULL
human	NULL
Bcl-2	NULL
.	NULL

MCF-Bcl-x.1	NULL
and	NULL
MCF-Bcl-x.2	NULL
are	NULL
two	NULL
pooled	NULL
populations	NULL
of	NULL
the	NULL
same	NULL
cells	NULL
successfully	NULL
transfected	NULL
with	NULL
a	NULL
similar	NULL
expression	NULL
construct	NULL
coding	NULL
for	NULL
human	NULL
Bcl-x	NULL
;	NULL
,	NULL
and	NULL
MCF-V.1	NULL
and	NULL
MCF-V.2	NULL
are	NULL
pools	NULL
of	NULL
MCF-Fas	NULL
cells	NULL
transfected	NULL
with	NULL
an	NULL
empty	NULL
vector	NULL
(	NULL
17	NULL
)	NULL
.	NULL

The	NULL
Fas-sensitive	NULL
BJAB	NULL
cells	NULL
,	NULL
a	NULL
B-cell	NULL
line	NULL
,	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
F.	NULL
Wang	NULL
(	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Cambridge	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

.	NULL

All	NULL
cells	NULL
were	NULL
cultured	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
humidified	NULL
air	NULL
atmosphere	NULL
with	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
.	NULL

RPMI	NULL
1640	NULL
medium	NULL
,	NULL
with	NULL
(	NULL
Gibco	NULL
Ltd.	NULL
,	NULL
Paisley	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
(	NULL
HyClone	NULL
)	NULL
,	NULL
streptomycin	NULL
(	NULL
10	NULL
mg/ml	NULL
)	NULL
,	NULL
and	NULL
penicillin	NULL
(	NULL
100	NULL
U/m1	NULL
)	NULL
,	NULL
was	NULL
used	NULL
as	NULL
a	NULL
growth	NULL
medium	NULL
for	NULL
all	NULL
cell	NULL
lines	NULL
and	NULL
is	NULL
referred	NULL
to	NULL
as	NULL
complete	NULL
medium	NULL
(	NULL
CM	NULL
)	NULL
.	NULL

The	NULL
medium	NULL
used	NULL
for	NULL
the	NULL
culture	NULL
of	NULL
cell	NULL
lines	NULL
transfected	NULL
with	NULL
either	NULL
pREP4-	NULL
or	NULL
pEBS7-based	NULL
plasmids	NULL
was	NULL
supplemented	NULL
with	NULL
hygromycin	NULL
(	NULL
Calbiotech	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
Calif.	NULL
)	NULL
:	NULL
0.15	NULL
mg/ml	NULL
for	NULL
MCF7S1	NULL
and	NULL
MCF-Fas	NULL
cells	NULL
and	NULL
0.5	NULL
mg/ml	NULL
for	NULL
BJAB	NULL
cells	NULL
.	NULL

The	NULL
growth	NULL
medium	NULL
for	NULL
MCF-Fas	NULL
cells	NULL
was	NULL
further	NULL
supplemented	NULL
with	NULL
0.2	NULL
mg	NULL
of	NULL
G418	NULL
(	NULL
Gibco	NULL
)	NULL
per	NULL
ml	NULL
.	NULL

Recombinant	NULL
human	NULL
TNF	NULL
was	NULL
from	NULL
Genentech	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
Calif.	NULL
,	NULL
and	NULL
monoclonal	NULL
anti-Fas	NULL
antibody	NULL
(	NULL
anti-APO1	NULL
[	NULL
54	NULL
]	NULL
)	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
P.	NULL
Krammer	NULL
(	NULL
German	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
Heidelberg	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Plasmids	NULL
.	NULL

pREP4	NULL
(	NULL
Invitrogen	NULL
)	NULL
is	NULL
an	NULL
episomal	NULL
eucaryotic	NULL
expression	NULL
vector	NULL
in	NULL
which	NULL
the	NULL
presence	NULL
of	NULL
both	NULL
the	NULL
EBV	NULL
origin	NULL
for	NULL
plasmid	NULL
replication	NULL
(	NULL
orfP	NULL
)	NULL
and	NULL
the	NULL
gene	NULL
encoding	NULL
Epstein-Barr	NULL
nuclear	NULL
antigen	NULL
1	NULL
allow	NULL
the	NULL
vector	NULL
to	NULL
replicate	NULL
extrachromosomally	NULL
.	NULL

The	NULL
plasmid	NULL
contains	NULL
a	NULL
gene	NULL
coding	NULL
for	NULL
hygromycin	NULL
phos-photransferase	NULL
,	NULL
which	NULL
confers	NULL
resistance	NULL
to	NULL
hygromycin	NULL
B.	NULL
Inserted	NULL
cDNA	NULL
in	NULL
a	NULL
multicloning	NULL
site	NULL
is	NULL
under	NULL
the	NULL
transcriptional	NULL
control	NULL
of	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
3	NULL
'	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

pRP-BHRF1	NULL
is	NULL
the	NULL
pREP4	NULL
plasmid	NULL
containing	NULL
cDNA	NULL
coding	NULL
for	NULL
BHRF1	NULL
.	NULL

pRP-Bgal	NULL
is	NULL
the	NULL
pREP4	NULL
plasmid	NULL
containing	NULL
cDNA	NULL
coding	NULL
for	NULL
the	NULL
Escherichia	NULL
coli	NULL
enzyme	NULL
B-galactosidase	NULL
.	NULL

pEBS7	NULL
is	NULL
also	NULL
an	NULL
EBV-based	NULL
episomal	NULL
vector	NULL
,	NULL
which	NULL
differs	NULL
from	NULL
pREP4	NULL
only	NULL
by	NULL
having	NULL
a	NULL
cytomegalovirus	NULL
promoter	NULL
(	NULL
17	NULL
)	NULL
.	NULL

pEBS7-Bcl-2	NULL
is	NULL
the	NULL
pEBS	NULL
?	NULL

7	NULL
plasmid	NULL
containing	NULL
the	NULL
cDNA	NULL
coding	NULL
for	NULL
human	NULL
Bel-2	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Functional	NULL
expression	NULL
,	NULL
cloning	NULL
,	NULL
and	NULL
sequencing	NULL
.	NULL

A	NULL
poly	NULL
(	NULL
T	NULL
)	NULL
-primed	NULL
cDNA	NULL
library	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
M.	NULL
Buchwald	NULL
,	NULL
University	NULL
of	NULL
Toronto	NULL
,	NULL
Toronto	NULL
,	NULL
On-tario	NULL
,	NULL
Canada	NULL
[	NULL
42	NULL
]	NULL
)	NULL
made	NULL
from	NULL
mRNA	NULL
from	NULL
TNF-resistant	NULL
EBV-transformed	NULL
lymphoblasts	NULL
cloned	NULL
into	NULL
vector	NULL
pREP4	NULL
was	NULL
used	NULL
in	NULL
the	NULL
expression	NULL
study	NULL
.	NULL

The	NULL
cDNA	NULL
library	NULL
consisted	NULL
of	NULL
5	NULL
x	NULL
10°	NULL
individual	NULL
colonies	NULL
,	NULL
and	NULL
gel	NULL
electrophoresis	NULL
of	NULL
released	NULL
inserts	NULL
revealed	NULL
a	NULL
continuous	NULL
DNA	NULL
smear	NULL
ranging	NULL
in	NULL
size	NULL
from	NULL
approximately	NULL
300	NULL
to	NULL
4,000	NULL
bp	NULL
.	NULL

The	NULL
cDNA	NULL
library	NULL
was	NULL
introduced	NULL
to	NULL
the	NULL
highly	NULL
TNF-sensitive	NULL
MCF7S1	NULL
cells	NULL
by	NULL
electroporation	NULL
;	NULL
4	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
20	NULL
to	NULL
60	NULL
g	NULL
of	NULL
library	NULL
DNA	NULL
ml~*	NULL
,	NULL
resuspended	NULL
in	NULL
CM	NULL
,	NULL
transferred	NULL
to	NULL
tissue	NULL
culture	NULL
flasks	NULL
,	NULL
and	NULL
incubated	NULL
at	NULL
37°C	NULL
.	NULL

Two	NULL
days	NULL
later	NULL
hygromycin	NULL
(	NULL
150	NULL
U/m	NULL
!	NULL

1	NULL
)	NULL
was	NULL
added	NULL
,	NULL
and	NULL
the	NULL
incubation	NULL
was	NULL
continued	NULL
for	NULL
5	NULL
to	NULL
8	NULL
days	NULL
to	NULL
allow	NULL
drug-resistant	NULL
clones	NULL
to	NULL
reach	NULL
confluence	NULL
.	NULL

To	NULL
obtain	NULL
TNF-resistant	NULL
clones	NULL
,	NULL
hygromycin-resistant	NULL
clones	NULL
were	NULL
treated	NULL
with	NULL
50	NULL
to	NULL
100	NULL
ng	NULL
of	NULL
TNF	NULL
per	NULL
ml	NULL
for	NULL
24	NULL
h	NULL
and	NULL
incubated	NULL
in	NULL
CM	NULL
containing	NULL
hygromycin	NULL
(	NULL
150	NULL
U/m	NULL
!	NULL
)	NULL

until	NULL
they	NULL
reached	NULL
subconfluence	NULL
.	NULL

Thereafter	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
trypsinized	NULL
and	NULL
plated	NULL
on	NULL
petri	NULL
dishes	NULL
,	NULL
and	NULL
treatment	NULL
with	NULL
TNF	NULL
was	NULL
repeated	NULL
.	NULL

When	NULL
the	NULL
cells	NULL
reached	NULL
confluence	NULL
following	NULL
the	NULL
second	NULL
TNF	NULL
treat-ment	NULL
,	NULL
episomal	NULL
plasmid	NULL
DNA	NULL
was	NULL
recovered	NULL
by	NULL
Hirt	NULL
extraction	NULL
(	NULL
14	NULL
)	NULL
and	NULL
introduced	NULL
into	NULL
DH10B	NULL
electrocompetent	NULL
bacteria	NULL
(	NULL
Gibco	NULL
)	NULL
by	NULL
electroporation	NULL
,	NULL
as	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

Transformants	NULL
were	NULL
plated	NULL
on	NULL
Luria-Bertani	NULL
agar-ampicillin	NULL
(	NULL
120	NULL
ug/ml	NULL
!	NULL
)	NULL

plates	NULL
and	NULL
incubated	NULL
for	NULL
16	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Colonies	NULL
were	NULL
resuspended	NULL
in	NULL
Luria-Bertani	NULL
medium	NULL
(	NULL
by	NULL
using	NULL
a	NULL
rubber	NULL
policeman	NULL
)	NULL
and	NULL
incubated	NULL
in	NULL
a	NULL
bacterial	NULL
shaker	NULL
for	NULL
24	NULL
h	NULL
at	NULL
37°C	NULL
,	NULL
and	NULL
large-scale	NULL
plasmid	NULL
DNA	NULL
was	NULL
prepared	NULL
by	NULL
standard	NULL
methods	NULL
.	NULL

DNA	NULL
sequences	NULL
were	NULL
determined	NULL
by	NULL
T7	NULL
DNA	NULL
polymerase	NULL
(	NULL
Sequenase	NULL
,	NULL
version	NULL
2.0	NULL
;	NULL
U.S.	NULL
Biochemicals	NULL
,	NULL
Cleveland	NULL
,	NULL
Ohio	NULL
)	NULL
following	NULL
the	NULL
protocol	NULL
suggested	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

Electroporation	NULL
.	NULL

Circular	NULL
plasmid	NULL
DNA	NULL
was	NULL
introduced	NULL
into	NULL
cells	NULL
by	NULL
electroporation	NULL
;	NULL
2	NULL
X	NULL
10	NULL
``	NULL
to	NULL
4	NULL
X	NULL
10	NULL
``	NULL
cells	NULL
in	NULL
logarithmic	NULL
growth	NULL
were	NULL
trypsinized	NULL
,	NULL
resuspended	NULL
in	NULL
0.8	NULL
ml	NULL
of	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
containing	NULL
20	NULL
to	NULL
60	NULL
ug	NULL
of	NULL
plasmid	NULL
DNA	NULL
,	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
10	NULL
min	NULL
,	NULL
and	NULL
transferred	NULL
to	NULL
an	NULL
electroporation	NULL
cuvette	NULL
.	NULL

Following	NULL
delivery	NULL
of	NULL
an	NULL
electric	NULL
pulse	NULL
(	NULL
capacitance	NULL
,	NULL
960	NULL
wF	NULL
;	NULL
voltage	NULL
,	NULL
850	NULL
V/cm	NULL
;	NULL
resulting	NULL
time	NULL
constant	NULL
,	NULL
11	NULL
to	NULL
13	NULL
ms	NULL
)	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
cuvette	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
5	NULL
min	NULL
before	NULL
resuspension	NULL
in	NULL
20	NULL
ml	NULL
of	NULL
CM	NULL
and	NULL
transfer	NULL
into	NULL
75-cm	NULL
>	NULL
tissue	NULL
culture	NULL
flasks	NULL
.	NULL

After	NULL
48	NULL
h	NULL
at	NULL
37°C	NULL
,	NULL
J.	NULL
Viror	NULL
.	NULL

hygromycin	NULL
was	NULL
added	NULL
and	NULL
the	NULL
incubation	NULL
was	NULL
continued	NULL
until	NULL
drug-resistant	NULL
clones	NULL
reached	NULL
confluence	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
.	NULL

Cells	NULL
,	NULL
1	NULL
X	NULL
10°	NULL
to	NULL
3	NULL
X	NULL
10°	NULL
per	NULL
lane	NULL
,	NULL
lysed	NULL
in	NULL
Laemmli	NULL
sample	NULL
buffer	NULL
(	NULL
23	NULL
)	NULL
or	NULL
urea	NULL
buffer	NULL
followed	NULL
by	NULL
sonication	NULL
,	NULL
were	NULL
resolved	NULL
in	NULL
a	NULL
sodium	NULL
dodecyl	NULL
sulfate-12	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
and	NULL
transferred	NULL
to	NULL
Hybond	NULL
ECL	NULL
filter	NULL
paper	NULL
(	NULL
Amersham	NULL
International	NULL
,	NULL
Buckinghamshire	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
with	NULL
an	NULL
electroblotter	NULL
(	NULL
Millipore	NULL
)	NULL
.	NULL

Filters	NULL
were	NULL
blocked	NULL
by	NULL
incubation	NULL
with	NULL
5	NULL
%	NULL
low-fat	NULL
milk	NULL
powder	NULL
in	NULL
Tris-buffered	NULL
saline	NULL
(	NULL
TBS	NULL
)	NULL
at	NULL
25°C	NULL
for	NULL
1	NULL
h	NULL
and	NULL
washed	NULL
twice	NULL
in	NULL
TBS	NULL
containing	NULL
0.05	NULL
%	NULL
Tween	NULL
20	NULL
(	NULL
washing	NULL
buffer	NULL
)	NULL
.	NULL

The	NULL
filters	NULL
were	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
25°C	NULL
or	NULL
for	NULL
18	NULL
h	NULL
at	NULL
4°C	NULL
with	NULL
primary	NULL
antibodies	NULL
diluted	NULL
in	NULL
the	NULL
following	NULL
concentrations	NULL
in	NULL
washing	NULL
buffer	NULL
containing	NULL
0.5	NULL
%	NULL
low-fat	NULL
milk	NULL
powder	NULL
:	NULL
anti-BHRF1	NULL
,	NULL
from	NULL
Advanced	NULL
Biotechnologies	NULL
Inc.	NULL
,	NULL
1:4,000	NULL
;	NULL
anti-Bcl-2	NULL
,	NULL
kindly	NULL
provided	NULL
by	NULL
G.	NULL
Nunez	NULL
,	NULL
1:500	NULL
;	NULL
and	NULL
anti-PARP	NULL
,	NULL
kindly	NULL
provided	NULL
by	NULL
G.	NULL
G.	NULL
Poirier	NULL
,	NULL
1:10,000	NULL
.	NULL

Following	NULL
three	NULL
washes	NULL
,	NULL
the	NULL
filters	NULL
were	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
25°C	NULL
in	NULL
washing	NULL
buffer	NULL
containing	NULL
a	NULL
1:40,000	NULL
dilution	NULL
of	NULL
peroxidase-conjugated	NULL
secondary	NULL
antibody	NULL
(	NULL
Dako	NULL
Immunoglobulins	NULL
,	NULL
Glostrup	NULL
,	NULL
Denmark	NULL
)	NULL
and	NULL
5	NULL
%	NULL
low-fat	NULL
milk	NULL
powder	NULL
.	NULL

After	NULL
the	NULL
filters	NULL
were	NULL
washed	NULL
thoroughly	NULL
,	NULL
the	NULL
chemiluminescence	NULL
reaction	NULL
was	NULL
performed	NULL
and	NULL
they	NULL
were	NULL
exposed	NULL
to	NULL
ECL	NULL
hyperfilm	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Cell	NULL
viability	NULL
assay	NULL
.	NULL

The	NULL
microculture	NULL
tetrazolium	NULL
assay	NULL
was	NULL
used	NULL
to	NULL
measure	NULL
the	NULL
viability	NULL
of	NULL
cells	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
approximately	NULL
5,000	NULL
(	NULL
MCF7S1	NULL
or	NULL
MCF-Fas	NULL
)	NULL
or	NULL
20,000	NULL
(	NULL
BJAB	NULL
)	NULL
target	NULL
cells	NULL
per	NULL
well	NULL
were	NULL
plated	NULL
in	NULL
96-well	NULL
microtiter	NULL
plates	NULL
in	NULL
0.1	NULL
ml	NULL
of	NULL
CM	NULL
,	NULL
in	NULL
medium	NULL
containing	NULL
the	NULL
indicated	NULL
amounts	NULL
(	NULL
see	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
of	NULL
TNF	NULL
and	NULL
anti-Fas	NULL
antibody	NULL
together	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
protein	NULL
A	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

per	NULL
ml	NULL
,	NULL
or	NULL
in	NULL
RPMI	NULL
supplemented	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
FCS	NULL
.	NULL

After	NULL
the	NULL
indicated	NULL
times	NULL
(	NULL
see	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
at	NULL
37°C	NULL
,	NULL
25	NULL
pil	NULL
of	NULL
dimethylthiazoly	NULL
]	NULL
tetrazolium	NULL
solution	NULL
(	NULL
MTT	NULL
)	NULL
(	NULL
5	NULL
mg/ml	NULL
;	NULL
Sigma	NULL
)	NULL
was	NULL
added	NULL
and	NULL
the	NULL
incubation	NULL
was	NULL
continued	NULL
for	NULL
3	NULL
h	NULL
before	NULL
addition	NULL
of	NULL
100	NULL
pl	NULL
of	NULL
lysis	NULL
buffer	NULL
(	NULL
20	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
in	NULL
a	NULL
50	NULL
%	NULL
solution	NULL
of	NULL
N	NULL
,	NULL
N-dimethylformamide	NULL
[	NULL
pH	NULL
4.5	NULL
]	NULL
)	NULL
.	NULL

Forming	NULL
formazan	NULL
crystals	NULL
were	NULL
allowed	NULL
to	NULL
dissolve	NULL
for	NULL
16	NULL
h	NULL
before	NULL
the	NULL
plates	NULL
were	NULL
read	NULL
on	NULL
a	NULL
microplate	NULL
reader	NULL
,	NULL
using	NULL
a	NULL
wavelength	NULL
of	NULL
550	NULL
nm	NULL
.	NULL

Effector	NULL
cells	NULL
.	NULL

Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMC	NULL
)	NULL
were	NULL
isolated	NULL
from	NULL
fresh	NULL
heparinized	NULL
blood	NULL
obtained	NULL
from	NULL
healthy	NULL
donors	NULL
at	NULL
the	NULL
University	NULL
Hospital	NULL
of	NULL
Copenhagen	NULL
(	NULL
Rigshospitalet	NULL
)	NULL
.	NULL

Sixty	NULL
milliliters	NULL
of	NULL
blood	NULL
was	NULL
mixed	NULL
and	NULL
resuspended	NULL
in	NULL
60	NULL
ml	NULL
of	NULL
PBS	NULL
.	NULL

PBMC	NULL
were	NULL
obtained	NULL
by	NULL
centrifugation	NULL
of	NULL
erythrocytes	NULL
through	NULL
a	NULL
Ficoll-Pague	NULL
Plus	NULL
(	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
layer	NULL
and	NULL
collection	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
interphase	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
two	NULL
times	NULL
in	NULL
PBS	NULL
,	NULL
resuspended	NULL
in	NULL
CM	NULL
,	NULL
and	NULL
incubated	NULL
on	NULL
petri	NULL
dishes	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
1	NULL
10°	NULL
to	NULL
3	NULL
X	NULL
10	NULL
%	NULL
/cm	NULL
>	NULL
in	NULL
order	NULL
to	NULL
isolate	NULL
the	NULL
monocytes	NULL
;	NULL
the	NULL
monocytes	NULL
adhered	NULL
to	NULL
the	NULL
surface	NULL
while	NULL
the	NULL
rest	NULL
of	NULL
the	NULL
mononuclear	NULL
cells	NULL
rested	NULL
in	NULL
solution	NULL
.	NULL

To	NULL
obtain	NULL
lymphokine-activated	NULL
killer	NULL
(	NULL
LAK	NULL
)	NULL
cells	NULL
,	NULL
the	NULL
nonadherent	NULL
cells	NULL
were	NULL
resuspended	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
1	NULL
X	NULL
10°	NULL
to	NULL
2	NULL
X	NULL
10°	NULL
cells/ml	NULL
in	NULL
CM	NULL
supplemented	NULL
with	NULL
interleukin-2	NULL
(	NULL
300	NULL
U/ml	NULL
;	NULL
Amersham	NULL
)	NULL
and	NULL
incubated	NULL
for	NULL
3	NULL
to	NULL
5	NULL
days	NULL
at	NULL
37°C	NULL
.	NULL

To	NULL
obtain	NULL
monocytes	NULL
,	NULL
the	NULL
adherent	NULL
cells	NULL
were	NULL
collected	NULL
with	NULL
a	NULL
rubber	NULL
policeman	NULL
,	NULL
resuspended	NULL
in	NULL
4	NULL
ml	NULL
of	NULL
CM	NULL
and	NULL
centrifuged	NULL
through	NULL
a	NULL
Percoll	NULL
layer	NULL
consisting	NULL
of	NULL
43	NULL
%	NULL
Percoll	NULL
(	NULL
Pharmacia	NULL
)	NULL
and	NULL
57	NULL
%	NULL
CM	NULL
.	NULL

The	NULL
cell	NULL
layer	NULL
in	NULL
the	NULL
interphase	NULL
was	NULL
collected	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
resuspended	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
10°	NULL
cells/ml	NULL
in	NULL
CM	NULL
supplemented	NULL
with	NULL
£	NULL
.	NULL

coli	NULL
lipopolysaccharide	NULL
(	NULL
0.5	NULL
ug/ml	NULL
;	NULL
Sigma	NULL
)	NULL
and	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
1	NULL
h.	NULL
Cytotoxicity	NULL
assay	NULL
.	NULL

Target	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10°	NULL
to	NULL
2	NULL
X	NULL
10°	NULL
cells/ml	NULL
)	NULL
were	NULL
labeled	NULL
with	NULL
sodium	NULL
(	NULL
0.1	NULL
NEN	NULL
,	NULL
Boston	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

in	NULL
CM	NULL
for	NULL
1	NULL
h	NULL
and	NULL
washed	NULL
twice	NULL
in	NULL
PBS	NULL
.	NULL

The	NULL
assay	NULL
was	NULL
set	NULL
up	NULL
in	NULL
triplicate	NULL
in	NULL
96-well	NULL
microtiter	NULL
plates	NULL
(	NULL
Greiner	NULL
)	NULL
.	NULL

Target	NULL
cell	NULL
suspension	NULL
,	NULL
5,000	NULL
cells	NULL
in	NULL
0.1	NULL
ml	NULL
of	NULL
CM	NULL
,	NULL
was	NULL
added	NULL
to	NULL
each	NULL
well	NULL
with	NULL
0.1-ml	NULL
dilutions	NULL
of	NULL
effector	NULL
cells	NULL
,	NULL
TNF	NULL
,	NULL
or	NULL
anti-Fas	NULL
antibody	NULL
in	NULL
CM	NULL
.	NULL

After	NULL
incubation	NULL
for	NULL
the	NULL
required	NULL
time	NULL
at	NULL
37°C	NULL
,	NULL
``	NULL
Cr	NULL
released	NULL
into	NULL
0.1	NULL
ml	NULL
of	NULL
supernatant	NULL
from	NULL
each	NULL
well	NULL
was	NULL
determined	NULL
with	NULL
an	NULL
automatic	NULL
gamma	NULL
counter	NULL
.	NULL

Assay	NULL
for	NULL
phospholipase	NULL
A	NULL
;	NULL
activity	NULL
.	NULL

The	NULL
incorporation	NULL
of	NULL
acid	NULL
into	NULL
membrane	NULL
phospholipids	NULL
of	NULL
intact	NULL
cells	NULL
was	NULL
done	NULL
essentially	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
in	NULL
5	NULL
ml	NULL
of	NULL
CM	NULL
supplemented	NULL
with	NULL
[	NULL
5,6,8,9,11,12,14,15-N-*HJarachidonic	NULL
acid	NULL
(	NULL
0.3	NULL
mCi/ml	NULL
;	NULL
NEN	NULL
)	NULL
were	NULL
plated	NULL
in	NULL
10-cm-diameter	NULL
petri	NULL
dishes	NULL
.	NULL

After	NULL
16	NULL
h	NULL
at	NULL
37°C	NULL
,	NULL
cells	NULL
were	NULL
scraped	NULL
with	NULL
a	NULL
rubber	NULL
policeman	NULL
,	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
PBS	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
CM	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
4	NULL
X	NULL
10°	NULL
%	NULL
/ml	NULL
.	NULL

The	NULL
assay	NULL
was	NULL
set	NULL
up	NULL
in	NULL
triplicate	NULL
in	NULL
24-well	NULL
microtiter	NULL
plates	NULL
by	NULL
adding	NULL
0.5	NULL
ml	NULL
of	NULL
cell	NULL
suspension	NULL
to	NULL
each	NULL
well	NULL
with	NULL
0.1	NULL
ml	NULL
of	NULL
CM	NULL
or	NULL
medium	NULL
containing	NULL
the	NULL
indicated	NULL
dilutions	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
of	NULL
TNF	NULL
or	NULL
anti-Fas	NULL
antibody	NULL
.	NULL

After	NULL
18	NULL
h	NULL
at	NULL
37°C	NULL
,	NULL
the	NULL
plates	NULL
were	NULL
centrifuged	NULL
at	NULL
1,000	NULL
x	NULL
g	NULL
and	NULL
0.3	NULL
ml	NULL
of	NULL
the	NULL
supernatant	NULL
was	NULL
collected	NULL
,	NULL
mixed	NULL
with	NULL
3	NULL
ml	NULL
of	NULL
Ecosint	NULL
A	NULL
scintillation	NULL
fluid	NULL
(	NULL
National	NULL
Diagnostics	NULL
,	NULL
Manville	NULL
,	NULL
N.J.	NULL
)	NULL
,	NULL
and	NULL
analyzed	NULL
in	NULL
a	NULL
scintillation	NULL
counter	NULL
.	NULL

The	NULL
radioactivity	NULL
of	NULL
°H	NULL
released	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
TNF	NULL
or	NULL
anti-Fas	NULL
antibody	NULL
was	NULL
compared	NULL
with	NULL
the	NULL
average	NULL
radioactivity	NULL
of	NULL
°H	NULL
released	NULL
from	NULL
cells	NULL
incubated	NULL
with	NULL
medium	NULL
alone	NULL
and	NULL
was	NULL
expressed	NULL
as	NULL
a	NULL
percentage	NULL
,	NULL
with	NULL
the	NULL
spontancous	NULL
value	NULL
being	NULL
100	NULL
%	NULL
.	NULL

The	NULL
spontaneous	NULL
release	NULL
of	NULL
arachidonic	NULL
acid	NULL
from	NULL
untreated	NULL
cells	NULL
was	NULL
always	NULL
less	NULL
than	NULL
10	NULL
%	NULL
of	NULL
the	NULL
total	NULL
.	NULL

Transient	NULL
transfection	NULL
and	NULL
luciferase	NULL
assay	NULL
.	NULL

Five	NULL
micrograms	NULL
of	NULL
plasmid	NULL
pBlIx	NULL
,	NULL
containing	NULL
NF-kB	NULL
binding	NULL
sequences	NULL
from	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
,	NULL
or	NULL
pAP-LUC	NULL
,	NULL
containing	NULL
an	NULL
AP-1	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
human	NULL
collagenase	NULL
gene	NULL
upstream	NULL
from	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
,	NULL
was	NULL
cotransfected	NULL
with	NULL
3	NULL
ug	NULL
of	NULL
plasmid	NULL
pEBS-BGal	NULL
into	NULL
2	NULL
X	NULL
10°	NULL
to	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
,	NULL
essentially	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
18	NULL
,	NULL
22	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Two	NULL
days	NULL
after	NULL
transfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
left	NULL
untreated	NULL
or	NULL
were	NULL
treated	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
of	NULL
TNF	NULL
4	NULL
h	NULL
before	NULL
harvesting	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
measured	NULL
with	NULL
the	NULL
Promega	NULL
luciferase	NULL
assay	NULL
voL	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
system	NULL
.	NULL

The	NULL
lysates	NULL
used	NULL
for	NULL
the	NULL
luciferase	NULL
assay	NULL
were	NULL
also	NULL
tested	NULL
for	NULL
B-galacto-sidase	NULL
activity	NULL
(	NULL
control	NULL
for	NULL
transfection	NULL
efficiency	NULL
)	NULL
by	NULL
using	NULL
ortho-nitrophenyl-B-p-galactopyranoside	NULL
(	NULL
Sigma	NULL
)	NULL
as	NULL
a	NULL
chromogenic	NULL
substrate	NULL
,	NULL
and	NULL
the	NULL
values	NULL
from	NULL
the	NULL
luciferase	NULL
assay	NULL
were	NULL
corrected	NULL
accordingly	NULL
.	NULL

RESULTS	NULL
Cloning	NULL
of	NULL
BHRF1	NULL
by	NULL
functional	NULL
expression	NULL
cloning	NULL
.	NULL

To	NULL
identify	NULL
proteins	NULL
that	NULL
protect	NULL
cells	NULL
from	NULL
the	NULL
cytotoxic	NULL
effects	NULL
of	NULL
TNF	NULL
,	NULL
a	NULL
cDNA	NULL
library	NULL
originating	NULL
from	NULL
TNF-resistant	NULL
EBV-transformed	NULL
lymphoblasts	NULL
was	NULL
transfected	NULL
into	NULL
MCF7S1	NULL
cells	NULL
by	NULL
electroporation	NULL
.	NULL

Hygromycin-resistant	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
50	NULL
ng	NULL
of	NULL
TNF	NULL
per	NULL
ml	NULL
for	NULL
24	NULL
h	NULL
,	NULL
and	NULL
surviving	NULL
cells	NULL
(	NULL
0.1	NULL
to	NULL
1	NULL
%	NULL
)	NULL
were	NULL
allowed	NULL
to	NULL
reach	NULL
subconfluence	NULL
before	NULL
another	NULL
24-h	NULL
exposure	NULL
to	NULL
TNF	NULL
.	NULL

Episomal	NULL
plasmid	NULL
DNA	NULL
from	NULL
surviving	NULL
cells	NULL
was	NULL
recovered	NULL
by	NULL
HIRT	NULL
extraction	NULL
(	NULL
14	NULL
)	NULL
and	NULL
amplified	NULL
in	NULL
bac-teria	NULL
;	NULL
the	NULL
selection	NULL
process	NULL
was	NULL
repeated	NULL
three	NULL
times	NULL
.	NULL

The	NULL
resistance	NULL
of	NULL
transfected	NULL
cells	NULL
to	NULL
TNF	NULL
clearly	NULL
increased	NULL
by	NULL
each	NULL
round	NULL
,	NULL
and	NULL
a	NULL
plasmid	NULL
containing	NULL
a	NULL
cDNA	NULL
insert	NULL
of	NULL
approximately	NULL
1.7	NULL
kb	NULL
was	NULL
enriched	NULL
.	NULL

After	NULL
three	NULL
selection	NULL
rounds	NULL
,	NULL
the	NULL
1.7-kb	NULL
insert	NULL
was	NULL
found	NULL
in	NULL
approximately	NULL
5	NULL
%	NULL
of	NULL
the	NULL
plasmids	NULL
.	NULL

The	NULL
rescued	NULL
plasmid	NULL
containing	NULL
the	NULL
1.7-kb	NULL
insert	NULL
was	NULL
transfected	NULL
into	NULL
MCF7S1	NULL
cells	NULL
,	NULL
and	NULL
hygromycin-resistant	NULL
cells	NULL
were	NULL
tested	NULL
for	NULL
their	NULL
sensitivity	NULL
to	NULL
TNF	NULL
in	NULL
a	NULL
48-h	NULL
MTT	NULL
cell	NULL
viability	NULL
assay	NULL
(	NULL
28	NULL
)	NULL
.	NULL

The	NULL
sensitivity	NULL
was	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
hygromycin	NULL
B-resistant	NULL
MCF7S1	NULL
cells	NULL
transfected	NULL
in	NULL
parallel	NULL
with	NULL
an	NULL
empty	NULL
control	NULL
vector	NULL
,	NULL
pEBS7	NULL
.	NULL

The	NULL
1.7-kb	NULL
insert	NULL
clearly	NULL
protected	NULL
cells	NULL
from	NULL
the	NULL
TNF-induced	NULL
cytotoxicity	NULL
,	NULL
as	NULL
it	NULL
conferred	NULL
80	NULL
to	NULL
90	NULL
%	NULL
resistance	NULL
to	NULL
TNF	NULL
killing	NULL
at	NULL
concentrations	NULL
of	NULL
up	NULL
to	NULL
100	NULL
ng/ml	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
cDNA	NULL
was	NULL
then	NULL
sequenced	NULL
,	NULL
and	NULL
comparison	NULL
of	NULL
the	NULL
obtained	NULL
sequence	NULL
with	NULL
the	NULL
GenBank	NULL
database	NULL
revealed	NULL
nearly	NULL
complete	NULL
homology	NULL
(	NULL
99	NULL
%	NULL
)	NULL
to	NULL
published	NULL
cDNA	NULL
sequences	NULL
encoding	NULL
BHRF1	NULL
.	NULL

BHRF1	NULL
is	NULL
an	NULL
EBV	NULL
early	NULL
lytic	NULL
protein	NULL
with	NULL
a	NULL
molecular	NULL
mass	NULL
of	NULL
17	NULL
kDa	NULL
.	NULL

BHRF1	NULL
displays	NULL
limited	NULL
homology	NULL
to	NULL
Bcl-2	NULL
,	NULL
with	NULL
the	NULL
alignment	NULL
of	NULL
BHRF1	NULL
and	NULL
Bcl-2	NULL
revealing	NULL
approximately	NULL
25	NULL
%	NULL
amino	NULL
acid	NULL
identity	NULL
.	NULL

BHRF1	NULL
protects	NULL
MCF-Fas	NULL
cells	NULL
from	NULL
TNF-	NULL
and	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

To	NULL
allow	NULL
a	NULL
comparison	NULL
of	NULL
TNF-	NULL
and	NULL
Fas-induced	NULL
killing	NULL
in	NULL
the	NULL
same	NULL
cell	NULL
line	NULL
,	NULL
MCF7	NULL
cells	NULL
successfully	NULL
transfected	NULL
with	NULL
human	NULL
Fas	NULL
cDNA	NULL
(	NULL
MCF-Fas	NULL
)	NULL
were	NULL
used	NULL
(	NULL
17	NULL
)	NULL
.	NULL

To	NULL
test	NULL
the	NULL
ability	NULL
of	NULL
BHRF1	NULL
to	NULL
protect	NULL
MCF-Fas	NULL
cells	NULL
from	NULL
anti-Fas-	NULL
and	NULL
TNF-mediated	NULL
apoptosis	NULL
,	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
pREP4	NULL
expression	NULL
vector	NULL
containing	NULL
the	NULL
cDNA	NULL
encoding	NULL
BHRF1	NULL
(	NULL
pRP-BHRF1	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
,	NULL
in	NULL
parallel	NULL
,	NULL
transfected	NULL
with	NULL
the	NULL
pREP4	NULL
vector	NULL
containing	NULL
cDNA	NULL
coding	NULL
for	NULL
B-galac-tosidase	NULL
or	NULL
with	NULL
a	NULL
closely	NULL
related	NULL
pEBS7	NULL
expression	NULL
plasmid	NULL
(	NULL
empty	NULL
vector	NULL
)	NULL
.	NULL

Two	NULL
independent	NULL
transfections	NULL
of	NULL
pRP-BHRF1	NULL
generated	NULL
two	NULL
hygromycin	NULL
B-resistant	NULL
cell	NULL
populations	NULL
(	NULL
MCF-BHRF1.1	NULL
and	NULL
MCF-BHRF1.2	NULL
)	NULL
that	NULL
stably	NULL
expressed	NULL
BHRF1	NULL
,	NULL
as	NULL
analyzed	NULL
by	NULL
Western	NULL
blotting	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
sensitivity	NULL
of	NULL
transfected	NULL
MCF-Fas	NULL
cells	NULL
to	NULL
TNF-	NULL
and	NULL
anti-Fas-mediated	NULL
apoptosis	NULL
was	NULL
analyzed	NULL
in	NULL
a	NULL
48-h	NULL
MTT	NULL
cell	NULL
viability	NULL
assay	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
the	NULL
control	NULL
cells	NULL
(	NULL
MCF-pEBS7	NULL
and	NULL
MCF-Bgal	NULL
)	NULL
were	NULL
killed	NULL
in	NULL
a	NULL
dose-dependent	NULL
man-ner	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
MCF-Fas	NULL
cells	NULL
expressing	NULL
BHRF1	NULL
were	NULL
nearly	NULL
completely	NULL
resistant	NULL
to	NULL
apoptosis	NULL
mediated	NULL
by	NULL
either	NULL
TNF	NULL
or	NULL
anti-Fas	NULL
.	NULL

The	NULL
degree	NULL
of	NULL
resistance	NULL
conferred	NULL
by	NULL
BHRF1	NULL
was	NULL
identical	NULL
to	NULL
that	NULL
obtained	NULL
by	NULL
overexpression	NULL
of	NULL
either	NULL
Bel-2	NULL
or	NULL
Bcl-x	NULL
,	NULL
in	NULL
MCF-Fas	NULL
cells	NULL
(	NULL
17	NULL
)	NULL
.	NULL

The	NULL
protective	NULL
effect	NULL
of	NULL
BHRF1	NULL
was	NULL
emphasized	NULL
by	NULL
the	NULL
morphological	NULL
changes	NULL
of	NULL
control	NULL
cells	NULL
versus	NULL
BHRF1-expressing	NULL
cells	NULL
after	NULL
stimulation	NULL
with	NULL
TNF	NULL
or	NULL
anti-Fas	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2¢	NULL
,	NULL
untreated	NULL
MCF-pEBS7	NULL
and	NULL
MCF-BHRF1.1	NULL
cells	NULL
grew	NULL
equally	NULL
well	NULL
and	NULL
were	NULL
morphologi-cally	NULL
alike	NULL
,	NULL
whereas	NULL
the	NULL
difference	NULL
was	NULL
clear	NULL
for	NULL
cells	NULL
treated	NULL
with	NULL
TNF	NULL
.	NULL

After	NULL
24	NULL
h	NULL
with	NULL
TNF	NULL
,	NULL
control	NULL
cells	NULL
displayed	NULL
morphological	NULL
alterations	NULL
typical	NULL
of	NULL
adherent	NULL
cells	NULL
undergoing	NULL
ap-	NULL
BHRFI	NULL
AND	NULL
APOPTOSIS	NULL
-	NULL
7511	NULL
po	NULL
'	NULL
A	NULL
&	NULL
y	NULL
&	NULL
4	NULL
¥	NULL
$	NULL
§	NULL
4	NULL
G44	NULL
.	NULL

€	NULL
16	NULL
kD	NULL
-m	NULL
me	NULL
<	NULL
4-	NULL
BHREF	NULL
!	NULL

6	NULL
kD	NULL
--	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Detection	NULL
of	NULL
BHRF1	NULL
expression	NULL
in	NULL
transfected	NULL
MCF-Fas	NULL
cells	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

MCF-Fas	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
pRP-BHRF1	NULL
(	NULL
MCF-BHRFL.1	NULL
and	NULL
MCF-BHRFL2	NULL
)	NULL
,	NULL
pRP-fgal	NULL
(	NULL
MCF-Bgal	NULL
)	NULL
,	NULL
or	NULL
pEBS7	NULL
(	NULL
MCF-pEBS7	NULL
)	NULL
by	NULL
electroporation	NULL
.	NULL

Cell	NULL
lysates	NULL
from	NULL
approximately	NULL
3	NULL
x	NULL
10°	NULL
hygromycin-resistant	NULL
cells	NULL
were	NULL
analyzed	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
employing	NULL
anti-BHRF1	NULL
antibody	NULL
(	NULL
Advanced	NULL
Biotechnologies	NULL
Inc.	NULL
)	NULL
and	NULL
ECL	NULL
reagents	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Molecular	NULL
mass	NULL
markers	NULL
are	NULL
indicated	NULL
on	NULL
the	NULL
left	NULL
.	NULL

optosis	NULL
,	NULL
becoming	NULL
rounded	NULL
,	NULL
condensed	NULL
,	NULL
and	NULL
detached	NULL
from	NULL
the	NULL
dish	NULL
,	NULL
whereas	NULL
BHRF1-expressing	NULL
cells	NULL
did	NULL
not	NULL
show	NULL
any	NULL
morphological	NULL
changes	NULL
.	NULL

The	NULL
same	NULL
pattern	NULL
of	NULL
morphological	NULL
changes	NULL
was	NULL
seen	NULL
following	NULL
treatment	NULL
with	NULL
anti-Fas	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

BHRF1	NULL
protects	NULL
MCF-Fas	NULL
cells	NULL
from	NULL
cytotoxicity	NULL
mediated	NULL
by	NULL
monocytes	NULL
and	NULL
serum	NULL
starvation	NULL
but	NULL
not	NULL
from	NULL
LAK	NULL
cells	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
BHRF1	NULL
protects	NULL
cells	NULL
from	NULL
mediators	NULL
of	NULL
cell	NULL
death	NULL
other	NULL
than	NULL
TNF	NULL
or	NULL
anti-Fas	NULL
,	NULL
the	NULL
killing	NULL
of	NULL
cells	NULL
by	NULL
activated	NULL
monocytes	NULL
,	NULL
LAK	NULL
cells	NULL
,	NULL
and	NULL
serum	NULL
starvation	NULL
were	NULL
tested	NULL
.	NULL

The	NULL
sensitivity	NULL
of	NULL
transfected	NULL
MCF-Fas	NULL
cells	NULL
to	NULL
killing	NULL
by	NULL
activated	NULL
monocytes	NULL
was	NULL
analyzed	NULL
by	NULL
an	NULL
18-h	NULL
chromium	NULL
release	NULL
assay	NULL
with	NULL
MCF-Fas	NULL
transfectants	NULL
as	NULL
target	NULL
cells	NULL
and	NULL
activated	NULL
monocytes	NULL
as	NULL
effector	NULL
cells	NULL
.	NULL

Control	NULL
cells	NULL
were	NULL
killed	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
ranging	NULL
from	NULL
3	NULL
to	NULL
38	NULL
%	NULL
at	NULL
effector-to-target	NULL
ratios	NULL
ranging	NULL
from	NULL
1:1	NULL
to	NULL
64:1	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
)	NULL
.	NULL

BHRF1	NULL
protected	NULL
cells	NULL
from	NULL
killing	NULL
by	NULL
monocytes	NULL
in	NULL
a	NULL
manner	NULL
similar	NULL
to	NULL
that	NULL
in	NULL
which	NULL
cells	NULL
were	NULL
protected	NULL
from	NULL
killing	NULL
by	NULL
TNF	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
and	NULL
2a	NULL
)	NULL
.	NULL

A	NULL
4-h	NULL
chromium	NULL
release	NULL
assay	NULL
with	NULL
LAK	NULL
cells	NULL
as	NULL
effector	NULL
cells	NULL
and	NULL
MCF-Fas	NULL
transfectants	NULL
as	NULL
target	NULL
cells	NULL
showed	NULL
that	NULL
BHRF1	NULL
was	NULL
unable	NULL
to	NULL
protect	NULL
cells	NULL
from	NULL
LAK-cell-mediated	NULL
killing	NULL
:	NULL
7	NULL
to	NULL
90	NULL
%	NULL
of	NULL
the	NULL
target	NULL
cells	NULL
were	NULL
killed	NULL
in	NULL
4	NULL
h	NULL
at	NULL
effector-to-target	NULL
cell	NULL
ratios	NULL
ranging	NULL
from	NULL
1:1	NULL
to	NULL
64:1	NULL
.	NULL

There	NULL
was	NULL
no	NULL
significant	NULL
difference	NULL
in	NULL
killing	NULL
of	NULL
cells	NULL
expressing	NULL
BHRF1	NULL
and	NULL
vector-transfected	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
MCF-Fas	NULL
cells	NULL
overexpressing	NULL
either	NULL
Bel-2	NULL
or	NULL
Bel-x	NULL
;	NULL
,	NULL
both	NULL
proteins	NULL
conferring	NULL
resistance	NULL
against	NULL
monocyte-mediated	NULL
cytotoxicity	NULL
but	NULL
failing	NULL
to	NULL
protect	NULL
cells	NULL
against	NULL
LAK	NULL
-cell-mediated	NULL
killing	NULL
(	NULL
Fig	NULL
.	NULL

3b	NULL
)	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
BHRF1	NULL
was	NULL
able	NULL
to	NULL
protect	NULL
cells	NULL
from	NULL
serum	NULL
starvation	NULL
,	NULL
the	NULL
survival	NULL
of	NULL
transfected	NULL
MCF-Fas	NULL
cells	NULL
in	NULL
low	NULL
serum	NULL
concentrations	NULL
(	NULL
0.5	NULL
to	NULL
2	NULL
%	NULL
)	NULL
was	NULL
tested	NULL
by	NULL
a	NULL
7-day	NULL
MTT	NULL
assay	NULL
.	NULL

The	NULL
survival	NULL
of	NULL
BHRF1-expressing	NULL
cells	NULL
was	NULL
approximately	NULL
twice	NULL
as	NULL
high	NULL
as	NULL
that	NULL
of	NULL
vector-transfected	NULL
control	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3¢c	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
BHRF1	NULL
to	NULL
protect	NULL
MCF-Fas	NULL
cells	NULL
from	NULL
serum	NULL
starvation	NULL
is	NULL
of	NULL
a	NULL
magnitude	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
Bel-2	NULL
or	NULL
Bel-x	NULL
,	NULL
,	NULL
(	NULL
18	NULL
)	NULL
.	NULL

BHRF1	NULL
does	NULL
not	NULL
interfere	NULL
with	NULL
activation	NULL
of	NULL
NF-KB-like	NULL
and	NULL
AP-1	NULL
transcription	NULL
factors	NULL
.	NULL

TNF	NULL
,	NULL
but	NULL
not	NULL
anti-Fas	NULL
,	NULL
activates	NULL
NF-kB-like	NULL
and	NULL
AP-1-like	NULL
transcription	NULL
factors	NULL
in	NULL
MCF-Fas	NULL
cells	NULL
(	NULL
17	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
analyze	NULL
if	NULL
the	NULL
expression	NULL
of	NULL
BHRF1	NULL
interferes	NULL
with	NULL
the	NULL
activation	NULL
of	NULL
these	NULL
two	NULL
transcription	NULL
factors	NULL
,	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
assay	NULL
was	NULL
used	NULL
employing	NULL
MCF-Fas	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
a	NULL
plasmid	NULL
containing	NULL
two	NULL
kB	NULL
7512	NULL
FOGHSGAARD	NULL
AND	NULL
JAATTELA	NULL
a	NULL
19	NULL
“	NULL
\A	NULL
’	NULL
/	NULL
‘	NULL
80	NULL
A	NULL
a	NULL
-	NULL
@	NULL
-	NULL
-	NULL
MCF-pEBST7	NULL
a	NULL
A	NULL
-	NULL
=O	NULL
-	NULL
-	NULL
MCF-betagal	NULL
s	NULL
A	NULL
--	NULL
&	NULL
-	NULL
-	NULL
MCF-BHAF11	NULL
G.	NULL
A	NULL
--	NULL
-	NULL
-	NULL
MCF-BHRF1.2	NULL
#	NULL
0	NULL
91	NULL
a_	NULL
\	NULL
s	NULL
]	NULL
*a	NULL
1	NULL
.S	NULL
~I	NULL
»	NULL
\\	NULL
‘	NULL
b	NULL
.	NULL

Ca	NULL
40	NULL
7	NULL
~	NULL
:	NULL
*~	NULL
``	NULL
3	NULL
~	NULL
~	NULL
o	NULL
20	NULL
r	NULL
0	NULL
5	NULL
25	NULL
125	NULL
TNF	NULL
Concentration	NULL
of	NULL
TNF	NULL
(	NULL
ng/ml	NULL
)	NULL
b	NULL
19	NULL
80	NULL
{	NULL
4	NULL
``	NULL
-o-	NULL
MCF-pEBST	NULL
~	NULL
``	NULL
has	NULL
-	NULL
®	NULL
-	NULL
MCF-betagal	NULL
®	NULL
-	NULL
so-	NULL
~	NULL
-R-	NULL
-	NULL
MCF-BHRF11	NULL
la	NULL
a	NULL
*	NULL
-i-	NULL
-	NULL
MCE-BHRE1.2	NULL
>	NULL
.	NULL

4	NULL
\	NULL
*	NULL
=	NULL
A	NULL
€	NULL
7	NULL
*	NULL
~	NULL
.3	NULL
40	NULL
=	NULL
A	NULL
\	NULL
>	NULL
4	NULL
N	NULL
~	NULL
~	NULL
``	NULL
o	NULL
.	NULL

~	NULL
-	NULL
wo	NULL
T	NULL
&	NULL
bud	NULL
~	NULL
®	NULL
20	NULL
=	NULL
m	NULL
0	NULL
r	NULL
0	NULL
1	NULL
5	NULL
25	NULL
anti-Fas	NULL
Concentration	NULL
of	NULL
anti-Fas	NULL
(	NULL
ng/ml	NULL
)	NULL
C	NULL
MCF-pEBS7	NULL
:	NULL
-TNF	NULL
_	NULL
MCF-pEBS7	NULL
:	NULL
+INF	NULL
\le	NULL
``	NULL
y.	NULL
Ts	NULL
ry	NULL
``	NULL
,	NULL
¥	NULL
I	NULL
‘	NULL
)	NULL
#	NULL
a*	NULL
s	NULL
4	NULL
<	NULL
4	NULL
J	NULL
f	NULL
:	NULL
rap	NULL
``	NULL
®	NULL
:	NULL
%	NULL
¥	NULL
e	NULL
*	NULL
£	NULL
*	NULL
¥f	NULL
7	NULL
.	NULL

4	NULL
$	NULL
%	NULL
*	NULL
-s	NULL
>	NULL
*	NULL
>	NULL
P	NULL
P	NULL
/	NULL
*	NULL
,	NULL
3	NULL
»	NULL
*	NULL
:	NULL
»	NULL
Py	NULL
3	NULL
m	NULL
Pr	NULL
ay	NULL
}	NULL
*	NULL
LIE	NULL
C	NULL
_	NULL
¥	NULL
MCF-BHRF1.1	NULL
:	NULL
-TNF	NULL
MCF-BHRFI.1	NULL
:	NULL
;	NULL
+INF	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

BHRF1	NULL
protects	NULL
MCF-Fas	NULL
cells	NULL
from	NULL
TNF-mediated	NULL
(	NULL
a	NULL
,	NULL
c	NULL
)	NULL
and	NULL
anti-Fas	NULL
antibody-mediated	NULL
(	NULL
b	NULL
)	NULL
apoptosis	NULL
.	NULL

Approximately	NULL
5,000	NULL
cells	NULL
per	NULL
well	NULL
were	NULL
plated	NULL
in	NULL
96-well	NULL
plates	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
TNF	NULL
or	NULL
anti-Fas	NULL
antibody	NULL
with	NULL
1	NULL
mg	NULL
of	NULL
protein	NULL
A	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
the	NULL
percentage	NULL
of	NULL
surviving	NULL
cells	NULL
was	NULL
analyzed	NULL
by	NULL
MTT	NULL
assay	NULL
after	NULL
a	NULL
2-day	NULL
incubation	NULL
(	NULL
a	NULL
and	NULL
b	NULL
)	NULL
.	NULL

Cell	NULL
pools	NULL
are	NULL
as	NULL
described	NULL
for	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

To	NULL
show	NULL
the	NULL
morphological	NULL
features	NULL
of	NULL
MCF-Fas	NULL
transfectants	NULL
treated	NULL
with	NULL
50	NULL
ng	NULL
of	NULL
TNF	NULL
per	NULL
ml	NULL
for	NULL
24	NULL
h	NULL
,	NULL
approximately	NULL
200,000	NULL
cells	NULL
per	NULL
well	NULL
were	NULL
plated	NULL
in	NULL
24-well	NULL
plates	NULL
in	NULL
CM	NULL
or	NULL
CM	NULL
containing	NULL
TNF	NULL
(	NULL
c	NULL
)	NULL
.	NULL

binding	NULL
motifs	NULL
(	NULL
pBIIX	NULL
)	NULL
or	NULL
a	NULL
human	NULL
AP-1	NULL
binding	NULL
motif	NULL
(	NULL
pAP-LUC	NULL
)	NULL
and	NULL
a	NULL
minimal	NULL
mouse	NULL
fos	NULL
promoter	NULL
upstream	NULL
from	NULL
the	NULL
firefly	NULL
luciferase	NULL
gene	NULL
(	NULL
17	NULL
,	NULL
18	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Exposure	NULL
of	NULL
vector-transfected	NULL
cells	NULL
to	NULL
10	NULL
ng	NULL
of	NULL
TNF	NULL
per	NULL
ml	NULL
for	NULL
4	NULL
h	NULL
resulted	NULL
in	NULL
a	NULL
100-fold	NULL
increase	NULL
in	NULL
NF-	NULL
«	NULL
B-driven	NULL
luciferase	NULL
activity	NULL
and	NULL
a	NULL
J.	NULL
Viror	NULL
.	NULL

E	NULL
morpess	NULL
?	NULL

Q	NULL
mor-sHaria	NULL
D0	NULL
mcoreHrfi2	NULL
80	NULL
3	NULL
.	NULL

3.5	NULL
s.	NULL
ad	NULL
60	NULL
40	NULL
Specific	NULL
cytotoxicity	NULL
(	NULL
%	NULL
)	NULL
20	NULL
E	NULL
0	NULL
4	NULL
64d	NULL
16:1	NULL
4:11	NULL
dif	NULL
6490	NULL
464	NULL
493	NULL
49	NULL
monocytes	NULL
LAK	NULL
cells	NULL
effector	NULL
:	NULL
target	NULL
ratio	NULL
p	NULL
19	NULL
]	NULL
®	NULL
M	NULL
7	NULL
]	NULL
a	NULL
£9	NULL
®	NULL
mcrBoxs	NULL
L	NULL
-F	NULL
x	NULL
MCF-Bol-x.2	NULL
r	NULL
?	NULL

[	NULL
A	NULL
~	NULL
1	NULL
]	NULL
Q	NULL
mor-Bc-21	NULL
1	NULL
L	NULL
(	NULL
al	NULL
Q	NULL
MCF-Be-22	NULL
A	NULL
[	NULL
4	NULL
E	NULL
60	NULL
~	NULL
f	NULL
:	NULL
[	NULL
§	NULL
0	NULL
l	NULL
A	NULL
[	NULL
A	NULL
H	NULL
HP	NULL
o	NULL
-	NULL
404	NULL
f	NULL
:	NULL
a	NULL
3	NULL
A	NULL
|	NULL
800	NULL
.	NULL

A	NULL
C	NULL
3	NULL
[	NULL
2	NULL
]	NULL
9	NULL
H	NULL
I4	NULL
a	NULL
&	NULL
m	NULL
F4	NULL
|	NULL
]	NULL
f	NULL
[	NULL
4	NULL
F	NULL
F	NULL
|	NULL
[	NULL
16:1	NULL
64:1	NULL
monocytes	NULL
LAK	NULL
cells	NULL
effector	NULL
:	NULL
target	NULL
ratio	NULL
Cc	NULL
70	NULL
60	NULL
<	NULL
50	NULL
+	NULL
©	NULL
s	NULL
~-	NULL
40	NULL
4	NULL
2	NULL
18	NULL
30	NULL
7	NULL
.3	NULL
P	NULL
on	NULL
<	NULL
,	NULL
``	NULL
morpcssr	NULL
&	NULL
-a-	NULL
-	NULL
MCF-BHRF1.1	NULL
--	NULL
-	NULL
-	NULL
MCF-BHRF1.2	NULL
10	NULL
4	NULL
0	NULL
u	NULL
u	NULL
u	NULL
t	NULL
0.0	NULL
0.5	NULL
1.0	NULL
1.5	NULL
2.0	NULL
FCS	NULL
(	NULL
%	NULL
)	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Effect	NULL
of	NULL
BHRF1	NULL
,	NULL
Bcl-2	NULL
,	NULL
or	NULL
Bel-x	NULL
,	NULL
,	NULL
on	NULL
the	NULL
sensitivity	NULL
of	NULL
MCF-Fas	NULL
cells	NULL
to	NULL
monocytes	NULL
,	NULL
LAK	NULL
cells	NULL
,	NULL
and	NULL
serum	NULL
starvation	NULL
.	NULL

The	NULL
sensitivity	NULL
of	NULL
transfected	NULL
MCF-Fas	NULL
cells	NULL
to	NULL
lipopolysaccharide-stimulated	NULL
monocytes	NULL
or	NULL
LAK	NULL
cells	NULL
was	NULL
analyzed	NULL
by	NULL
chromium	NULL
release	NULL
assay	NULL
.	NULL

Approximately	NULL
5,000	NULL
cells	NULL
labeled	NULL
with	NULL
sodium	NULL
were	NULL
plated	NULL
in	NULL
96-well	NULL
plates	NULL
with	NULL
the	NULL
indicated	NULL
effector-to-target	NULL
cell	NULL
ratios	NULL
for	NULL
18	NULL
h	NULL
in	NULL
the	NULL
monocyte	NULL
assay	NULL
and	NULL
4	NULL
h	NULL
in	NULL
the	NULL
LAK	NULL
cell	NULL
assay	NULL
(	NULL
a	NULL
and	NULL
b	NULL
)	NULL
.	NULL

To	NULL
test	NULL
the	NULL
sensitivity	NULL
of	NULL
cells	NULL
to	NULL
serum	NULL
starvation	NULL
,	NULL
approximately	NULL
5,000	NULL
cells	NULL
per	NULL
well	NULL
were	NULL
plated	NULL
in	NULL
96-well	NULL
plates	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
FCS	NULL
,	NULL
and	NULL
the	NULL
percentage	NULL
of	NULL
surviving	NULL
cells	NULL
was	NULL
analyzed	NULL
by	NULL
MTT	NULL
assay	NULL
after	NULL
a	NULL
7-day	NULL
incubation	NULL
(	NULL
c	NULL
)	NULL
.	NULL

Experiments	NULL
were	NULL
repeated	NULL
three	NULL
times	NULL
with	NULL
essentially	NULL
the	NULL
same	NULL
results	NULL
.	NULL

vou	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
a	NULL
80	NULL
MCF-pEBS7	NULL
n	NULL
MCF-BHRFI.1	NULL
‘	NULL
é	NULL
q	NULL
MCF-BHRFL2	NULL
2	NULL
60	NULL
3	NULL
6	NULL
400	NULL
l	NULL
f	NULL
:	NULL
-D	NULL
=	NULL
S	NULL
L4	NULL
p	NULL
40	NULL
-	NULL
4	NULL
i	NULL
A	NULL
3	NULL
4	NULL
|	NULL
M	NULL
eI	NULL
&	NULL
20-	NULL
e	NULL
k	NULL
3	NULL
5	NULL
n	NULL
'	NULL
3	NULL
0	NULL
4	NULL
fA	NULL
G	NULL
=/	NULL
0-—==	NULL
--	NULL
_m	NULL
.	NULL

spon	NULL
0,1	NULL
1	NULL
10	NULL
b	NULL
>	NULL
=n	NULL
MCF-pEBS	NULL
?	NULL

(	NULL
2	NULL
MCF-BHRF1.1	NULL
MCF-BHRF1.2	NULL
fay	NULL
£	NULL
2	NULL
&	NULL
d	NULL
k	NULL
.Z	NULL
3	NULL
o	NULL
3	NULL
9	NULL
%	NULL
S	NULL
B	NULL
o	NULL
3	NULL
~	NULL
.d	NULL
0	NULL
spon	NULL
1	NULL
10	NULL
100	NULL
Concentration	NULL
of	NULL
TNF	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

FIG	NULL
.	NULL

4	NULL
.	NULL

BHRF1	NULL
does	NULL
not	NULL
affect	NULL
TNF-induced	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B-like	NULL
(	NULL
a	NULL
)	NULL
and	NULL
AP-1	NULL
(	NULL
b	NULL
)	NULL
transcription	NULL
factors	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
plasmid	NULL
pBIIX	NULL
,	NULL
containing	NULL
two	NULL
copies	NULL
of	NULL
NF-kB	NULL
binding	NULL
sites	NULL
(	NULL
a	NULL
)	NULL
,	NULL
or	NULL
pAP-LUC	NULL
,	NULL
containing	NULL
an	NULL
AP-1	NULL
binding	NULL
site	NULL
upstream	NULL
of	NULL
the	NULL
Photinus	NULL
pyralis	NULL
luciferase	NULL
coding	NULL
sequence	NULL
(	NULL
b	NULL
)	NULL
.	NULL

The	NULL
efficiency	NULL
of	NULL
each	NULL
transfection	NULL
was	NULL
monitored	NULL
by	NULL
a	NULL
cotransfected	NULL
cytomegalovirus	NULL
promoter-driven	NULL
LacZ	NULL
construct	NULL
(	NULL
pEBS7-Bgal	NULL
)	NULL
.	NULL

Forty-eight	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
either	NULL
left	NULL
unstimulated	NULL
or	NULL
stimulated	NULL
for	NULL
4	NULL
h	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
TNF	NULL
before	NULL
harvesting	NULL
.	NULL

The	NULL
lysates	NULL
were	NULL
tested	NULL
for	NULL
luciferase	NULL
activity	NULL
and	NULL
B-galacto-sidase	NULL
activity	NULL
.	NULL

1.5-fold	NULL
increase	NULL
in	NULL
AP-1-driven	NULL
luciferase	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
BHRF1	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
activation	NULL
of	NULL
either	NULL
NF-kB-like	NULL
or	NULL
AP-1-like	NULL
transcription	NULL
factors	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
have	NULL
been	NULL
obtained	NULL
with	NULL
MCF-Fas	NULL
cells	NULL
overexpressing	NULL
Bel-2	NULL
or	NULL
Bel-x	NULL
,	NULL
,	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
cPLA	NULL
,	NULL
by	NULL
TNF	NULL
and	NULL
anti-Fas	NULL
is	NULL
inhibited	NULL
by	NULL
BHRF1	NULL
.	NULL

The	NULL
release	NULL
of	NULL
arachidonic	NULL
acid	NULL
from	NULL
membrane	NULL
phospholipids	NULL
by	NULL
cPLA	NULL
;	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
be	NULL
an	NULL
essential	NULL
link	NULL
in	NULL
TNF-	NULL
and	NULL
anti-Fas-mediated	NULL
cytotoxicity	NULL
and	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
inhibited	NULL
by	NULL
overexpression	NULL
of	NULL
Bel-2	NULL
or	NULL
Bel-x	NULL
,	NULL
(	NULL
17	NULL
)	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
BHRF1	NULL
was	NULL
able	NULL
to	NULL
inhibit	NULL
TNF-	NULL
or	NULL
anti-Fas-induced	NULL
activation	NULL
of	NULL
cPLA	NULL
,	NULL
,	NULL
the	NULL
release	NULL
of	NULL
radioactivity	NULL
from	NULL
cells	NULL
labeled	NULL
with	NULL
[	NULL
°HJarachidonic	NULL
acid	NULL
was	NULL
measured	NULL
.	NULL

An	NULL
18-h	NULL
exposure	NULL
of	NULL
vector-transfected	NULL
MCF-Fas	NULL
cells	NULL
(	NULL
MCF-pEBS	NULL
$	NULL
7	NULL
)	NULL
to	NULL
TNF	NULL
(	NULL
1	NULL
to	NULL
100	NULL
ng/ml	NULL
)	NULL
or	NULL
anti-Fas	NULL
(	NULL
1	NULL
to	NULL
25	NULL
ng/ml	NULL
)	NULL
induced	NULL
a	NULL
dose-dependent	NULL
release	NULL
of	NULL
radioactivity	NULL
,	NULL
the	NULL
maximum	NULL
release	NULL
being	NULL
2.0-fold	NULL
(	NULL
TNF	NULL
)	NULL
or	NULL
2.1-fold	NULL
(	NULL
anti-Fas	NULL
)	NULL
higher	NULL
than	NULL
the	NULL
release	NULL
from	NULL
cells	NULL
incubated	NULL
in	NULL
medium	NULL
alone	NULL
.	NULL

The	NULL
TNF-	NULL
or	NULL
anti-Fas-induced	NULL
activation	NULL
of	NULL
cPLA	NULL
,	NULL
in	NULL
MCF-Fas	NULL
cells	NULL
expressing	NULL
BHRF1	NULL
was	NULL
almost	NULL
completely	NULL
inhibited	NULL
when	NULL
com	NULL
BHRFI	NULL
AND	NULL
APOPTOSIS	NULL
-	NULL
7513	NULL
200	NULL
A	NULL
m	NULL
MCFpEBS7	NULL
A	NULL
vcreHrrid	NULL
Mor-BHRr12	NULL
100	NULL
7	NULL
PLA2-activity	NULL
(	NULL
in	NULL
%	NULL
)	NULL
0	NULL
A	NULL
u	NULL
spon	NULL
TNF	NULL
100	NULL
Concentration	NULL
of	NULL
TNF	NULL
or	NULL
anti-Fas	NULL
(	NULL
ng/ml	NULL
)	NULL
anti-Fas	NULL
25	NULL
spontane	NULL
|	NULL
TNF30	NULL
|	NULL
Fas	NULL
10	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

BHRF1	NULL
inhibits	NULL
the	NULL
activation	NULL
of	NULL
cPLA	NULL
;	NULL
(	NULL
a	NULL
)	NULL
and	NULL
caspase-3	NULL
(	NULL
b	NULL
)	NULL
induced	NULL
by	NULL
cither	NULL
TNF	NULL
or	NULL
anti-Fas	NULL
in	NULL
MCF-Fas	NULL
cells	NULL
.	NULL

cPLA	NULL
,	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
cells	NULL
labeled	NULL
with	NULL
[	NULL
*HJarachidonic	NULL
acid	NULL
.	NULL

The	NULL
assay	NULL
was	NULL
set	NULL
up	NULL
in	NULL
triplicate	NULL
in	NULL
24-well	NULL
microtiter	NULL
plates	NULL
by	NULL
adding	NULL
2	NULL
X	NULL
10°	NULL
cells	NULL
in	NULL
0.6	NULL
ml	NULL
of	NULL
medium	NULL
or	NULL
medium	NULL
containing	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
TNF	NULL
or	NULL
anti-Fas	NULL
plus	NULL
protein	NULL
A	NULL
;	NULL
after	NULL
18	NULL
h	NULL
of	NULL
incubation	NULL
at	NULL
37°C	NULL
,	NULL
0.3	NULL
ml	NULL
of	NULL
the	NULL
supernatant	NULL
was	NULL
collected	NULL
and	NULL
the	NULL
radioactivity	NULL
released	NULL
was	NULL
analyzed	NULL
in	NULL
a	NULL
scintillation	NULL
counter	NULL
.	NULL

The	NULL
spontancous	NULL
release	NULL
was	NULL
set	NULL
to	NULL
100	NULL
%	NULL
.	NULL

In	NULL
the	NULL
PARP	NULL
analysis	NULL
,	NULL
MCF-Fas	NULL
transfectants	NULL
were	NULL
exposed	NULL
to	NULL
TNF	NULL
(	NULL
30	NULL
ng/m	NULL
!	NULL
)	NULL

or	NULL
anti-Fas	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
24	NULL
h	NULL
,	NULL
after	NULL
which	NULL
cell	NULL
lysates	NULL
were	NULL
prepared	NULL
for	NULL
immunoblotting	NULL
with	NULL
the	NULL
anti-PARP	NULL
monoclonal	NULL
antibody	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
upper	NULL
band	NULL
represents	NULL
the	NULL
intact	NULL
protein	NULL
,	NULL
and	NULL
the	NULL
lower	NULL
band	NULL
denotes	NULL
the	NULL
signature	NULL
cleavage	NULL
product	NULL
.	NULL

The	NULL
migration	NULL
of	NULL
a	NULL
98-kDa	NULL
molecular	NULL
mass	NULL
marker	NULL
is	NULL
indicated	NULL
on	NULL
the	NULL
left	NULL
.	NULL

pared	NULL
to	NULL
the	NULL
vector-transfected	NULL
control	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5a	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
inhibition	NULL
by	NULL
BHRFI1	NULL
is	NULL
comparable	NULL
to	NULL
that	NULL
of	NULL
Bel-2	NULL
or	NULL
Bel-x	NULL
,	NULL
,	NULL
in	NULL
MCF-Fas	NULL
cells	NULL
(	NULL
17	NULL
)	NULL
.	NULL

BHRF1	NULL
inhibits	NULL
the	NULL
activation	NULL
of	NULL
caspase-3	NULL
.	NULL

To	NULL
see	NULL
whether	NULL
BHRF1	NULL
was	NULL
able	NULL
to	NULL
inhibit	NULL
the	NULL
TNF-	NULL
and	NULL
anti-Fas-induced	NULL
activation	NULL
of	NULL
CPP32/caspase-3	NULL
,	NULL
the	NULL
integrity	NULL
of	NULL
the	NULL
death	NULL
substrate	NULL
PARP	NULL
was	NULL
analyzed	NULL
.	NULL

Vector-transfected	NULL
MCF-Fas	NULL
cells	NULL
revealed	NULL
partial	NULL
cleavage	NULL
of	NULL
the	NULL
native	NULL
116-kDa	NULL
PARP	NULL
to	NULL
the	NULL
signature	NULL
85-kDa	NULL
proteolytic	NULL
fragment	NULL
within	NULL
a	NULL
24-h	NULL
exposure	NULL
to	NULL
TNF	NULL
(	NULL
30	NULL
ng/ml	NULL
)	NULL
or	NULL
anti-Fas	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
.	NULL

In	NULL
MCF-Fas	NULL
cells	NULL
expressing	NULL
BHRF1	NULL
there	NULL
were	NULL
no	NULL
detectable	NULL
levels	NULL
of	NULL
the	NULL
85-kDa	NULL
proteolytic	NULL
product	NULL
,	NULL
indicating	NULL
that	NULL
BHRF1	NULL
inhibits	NULL
the	NULL
activation	NULL
of	NULL
CPP32/caspase-3-like	NULL
proteases	NULL
(	NULL
Fig	NULL
.	NULL

5b	NULL
)	NULL
.	NULL

Simi-larly	NULL
,	NULL
TNF	NULL
and	NULL
anti-Fas	NULL
failed	NULL
to	NULL
induce	NULL
cleavage	NULL
of	NULL
PARP	NULL
to	NULL
the	NULL
85-kDa	NULL
fragment	NULL
in	NULL
MCF-Fas	NULL
cells	NULL
overexpressing	NULL
either	NULL
Bel-2	NULL
or	NULL
Bel-x	NULL
,	NULL
,	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

BHRF1	NULL
does	NULL
not	NULL
protect	NULL
BJAB	NULL
cells	NULL
from	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

As	NULL
shown	NULL
above	NULL
,	NULL
BHRF1	NULL
is	NULL
able	NULL
to	NULL
protect	NULL
MCF-Fas	NULL
cells	NULL
from	NULL
various	NULL
apoptotic	NULL
stimuli	NULL
,	NULL
such	NULL
as	NULL
TNF	NULL
,	NULL
Fas	NULL
,	NULL
monocytes	NULL
,	NULL
and	NULL
serum	NULL
starvation	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
BHRF1	NULL
is	NULL
a	NULL
general	NULL
inhibitor	NULL
of	NULL
apoptosis	NULL
and	NULL
functions	NULL
where	NULL
the	NULL
various	NULL
apoptotic	NULL
stimuli	NULL
converge	NULL
into	NULL
a	NULL
common	NULL
death	NULL
pathway	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
protection	NULL
against	NULL
apoptosis	NULL
is	NULL
a	NULL
universal	NULL
feature	NULL
of	NULL
BHRF1	NULL
,	NULL
which	NULL
could	NULL
contribute	NULL
to	NULL
the	NULL
pathogenesis	NULL
of	NULL
EBV	NULL
,	NULL
we	NULL
extended	NULL
the	NULL
studies	NULL
to	NULL
another	NULL
cell	NULL
line	NULL
,	NULL
a	NULL
human	NULL
7514	NULL
FOGHSGAARD	NULL
AND	NULL
JAATTELA	NULL
A	NULL
~	NULL
a	NULL
&	NULL
&	NULL
Cy	NULL
&	NULL
3	NULL
&	NULL
3	NULL
£	NULL
p°	NULL
@	NULL
A	NULL
$	NULL
J	NULL
$	NULL
$	NULL
@	NULL
@	NULL
@	NULL
.	NULL

&	NULL
16	NULL
kD	NULL
-	NULL
»	NULL
sites	NULL
<	NULL
-	NULL
BHRFI	NULL
6	NULL
kD	NULL
-m	NULL
A	NULL
~	NULL
b	NULL
al	NULL
w	NULL
$	NULL
o	NULL
qo	NULL
£	NULL
$	NULL
A	NULL
&	NULL
&	NULL
a	NULL
ad	NULL
$	NULL
o	NULL
2	NULL
$	NULL
°	NULL
$	NULL
is	NULL
4	NULL
.	NULL

&	NULL
&	NULL
a	NULL
36	NULL
kD	NULL
-m	NULL
»	NULL
30	NULL
kD	NULL
-m	NULL
«	NULL
Wt	NULL
-a-	NULL
Bci-2	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Detection	NULL
of	NULL
BHRF1	NULL
(	NULL
a	NULL
)	NULL
or	NULL
Bcl-2	NULL
(	NULL
b	NULL
)	NULL
in	NULL
transfected	NULL
BJAB	NULL
cells	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

BJAB	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
plasmid	NULL
pRP-BHRF1	NULL
(	NULL
BJAB-BHRF1	NULL
}	NULL
,	NULL
pEBS7-Bcl-2	NULL
(	NULL
BJAB-Bcl-2	NULL
)	NULL
,	NULL
pRP-Bgal	NULL
(	NULL
BJAB-fgal	NULL
)	NULL
,	NULL
or	NULL
pEBS7	NULL
(	NULL
BJAB-pEBS7	NULL
)	NULL
by	NULL
electroporation	NULL
.	NULL

Cell	NULL
lysates	NULL
from	NULL
approximately	NULL
3	NULL
X	NULL
10°	NULL
hygromycin-resistant	NULL
cells	NULL
were	NULL
analyzed	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

Molecular	NULL
mass	NULL
markers	NULL
are	NULL
indicated	NULL
on	NULL
the	NULL
left	NULL
.	NULL

EBV-negative	NULL
B-cell	NULL
line	NULL
,	NULL
BJAB	NULL
,	NULL
which	NULL
is	NULL
sensitive	NULL
to	NULL
Fas-mediated	NULL
cytotoxicity	NULL
but	NULL
resistant	NULL
to	NULL
killing	NULL
by	NULL
TNF	NULL
.	NULL

pRP-BHRF1	NULL
was	NULL
transfected	NULL
into	NULL
BJAB	NULL
cells	NULL
to	NULL
create	NULL
a	NULL
cell	NULL
population	NULL
constitutively	NULL
expressing	NULL
BHRF1	NULL
.	NULL

In	NULL
parallel	NULL
,	NULL
BJAB	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
pRP-fgal	NULL
expression	NULL
plasmid	NULL
or	NULL
an	NULL
empty	NULL
expression	NULL
vector	NULL
,	NULL
pEBS7	NULL
,	NULL
creating	NULL
two	NULL
control	NULL
cell	NULL
populations	NULL
.	NULL

In	NULL
order	NULL
to	NULL
compare	NULL
the	NULL
effect	NULL
of	NULL
BHRF1	NULL
with	NULL
that	NULL
of	NULL
Bel-2	NULL
,	NULL
BJAB	NULL
cells	NULL
were	NULL
also	NULL
transfected	NULL
with	NULL
the	NULL
pEBS7-Bcl-2	NULL
expression	NULL
plasmid	NULL
.	NULL

A	NULL
Western	NULL
blot	NULL
analysis	NULL
showed	NULL
expression	NULL
of	NULL
BHRF1	NULL
in	NULL
BJAB-BHRF1	NULL
cells	NULL
and	NULL
overexpression	NULL
of	NULL
Bel-2	NULL
in	NULL
BJAB-Bcl-2	NULL
cells	NULL
,	NULL
compared	NULL
to	NULL
the	NULL
endogenous	NULL
expression	NULL
in	NULL
control	NULL
transfected	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

The	NULL
sensitivity	NULL
of	NULL
transfected	NULL
cells	NULL
to	NULL
anti-Fas	NULL
was	NULL
tested	NULL
by	NULL
a	NULL
6-h	NULL
MTT	NULL
assay	NULL
.	NULL

A	NULL
comparison	NULL
between	NULL
BJAB	NULL
cells	NULL
expressing	NULL
BHRF1	NULL
and	NULL
the	NULL
parental	NULL
cell	NULL
line	NULL
,	NULL
the	NULL
control	NULL
transfected	NULL
cells	NULL
,	NULL
or	NULL
Bel-2-ex-pressing	NULL
cells	NULL
did	NULL
not	NULL
show	NULL
any	NULL
significant	NULL
difference	NULL
in	NULL
sensitivity	NULL
towards	NULL
anti-Fas	NULL
(	NULL
Fig	NULL
.	NULL

7a	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
forced	NULL
expression	NULL
of	NULL
BHRF1	NULL
or	NULL
Bel-2	NULL
did	NULL
not	NULL
protect	NULL
BJAB	NULL
cells	NULL
from	NULL
Fas-mediated	NULL
killing	NULL
.	NULL

BHRF1	NULL
protects	NULL
BJAB	NULL
cells	NULL
from	NULL
serum	NULL
starvation	NULL
.	NULL

As	NULL
the	NULL
expression	NULL
of	NULL
BHRF1	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
sensitivity	NULL
of	NULL
BJAB	NULL
cells	NULL
to	NULL
anti-Fas-mediated	NULL
apoptosis	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
BJAB-BHRF1	NULL
cells	NULL
were	NULL
protected	NULL
from	NULL
another	NULL
apoptotic	NULL
stimulus	NULL
,	NULL
serum	NULL
starvation	NULL
.	NULL

The	NULL
four	NULL
BJAB	NULL
transfectants	NULL
were	NULL
then	NULL
screened	NULL
for	NULL
survival	NULL
over	NULL
a	NULL
9-day	NULL
period	NULL
after	NULL
transfer	NULL
into	NULL
medium	NULL
with	NULL
a	NULL
reduced	NULL
(	NULL
0.5	NULL
%	NULL
)	NULL
FCS	NULL
content	NULL
.	NULL

An	NULL
aliquot	NULL
was	NULL
tested	NULL
for	NULL
cell	NULL
viability	NULL
by	NULL
MTT	NULL
assay	NULL
every	NULL
day	NULL
from	NULL
day	NULL
1	NULL
to	NULL
day	NULL
7	NULL
.	NULL

Every	NULL
second	NULL
day	NULL
,	NULL
the	NULL
MTT	NULL
assay	NULL
was	NULL
accompanied	NULL
by	NULL
counting	NULL
of	NULL
the	NULL
cells	NULL
in	NULL
trypan	NULL
blue	NULL
to	NULL
verify	NULL
that	NULL
the	NULL
cells	NULL
were	NULL
actually	NULL
dying	NULL
by	NULL
serum	NULL
starvation	NULL
.	NULL

BHRF1-expressing	NULL
BJAB	NULL
cells	NULL
showed	NULL
significantly	NULL
enhanced	NULL
survival	NULL
compared	NULL
to	NULL
control	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7b	NULL
)	NULL
.	NULL

After	NULL
5	NULL
days	NULL
of	NULL
incubation	NULL
,	NULL
30	NULL
%	NULL
of	NULL
the	NULL
BHRF1-expressing	NULL
cells	NULL
had	NULL
survived	NULL
serum	NULL
starvation	NULL
while	NULL
only	NULL
5	NULL
%	NULL
of	NULL
the	NULL
control	NULL
cells	NULL
were	NULL
alive	NULL
.	NULL

After	NULL
9	NULL
days	NULL
of	NULL
incu-	NULL
J.	NULL
Viror	NULL
.	NULL

a	NULL
100	NULL
-	NULL
-M-	NULL
-	NULL
BJAB	NULL
«	NULL
-	NULL
-O-	NULL
-	NULL
BJAB-pEBS7	NULL
8o	NULL
<	NULL
=-	NULL
®	NULL
-	NULL
-	NULL
BJAB-betagal	NULL
``	NULL
-=-	NULL
-	NULL
BJAB-BHRF1	NULL
BJAB-Bcl-2	NULL
©	NULL
é	NULL
,	NULL
60	NULL
3	NULL
§	NULL
404	NULL
-	NULL
>	NULL
20	NULL
A	NULL
\\	NULL
%	NULL
0	NULL
T	NULL
T	NULL
u	NULL
T	NULL
T	NULL
0,0	NULL
0,2	NULL
0,4	NULL
0,6	NULL
0,8	NULL
1,0	NULL
Concentration	NULL
of	NULL
anti-Fas	NULL
(	NULL
ng/ml	NULL
)	NULL
40	NULL
loa	NULL
K	NULL
BJAR-pEBST	NULL
[	NULL
]	NULL
BJAB-betagal	NULL
E	NULL
]	NULL
BJAB-BHARF1	NULL
F	NULL
BJAB-Bci-2	NULL
Viability	NULL
(	NULL
percent	NULL
of	NULL
day	NULL
0	NULL
,	NULL
%	NULL
)	NULL
verenencces	NULL
days	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Expression	NULL
of	NULL
BHRF1	NULL
or	NULL
overexpression	NULL
of	NULL
Bel-2	NULL
does	NULL
not	NULL
protect	NULL
BJAB	NULL
cells	NULL
from	NULL
anti-Fas-mediated	NULL
apoptosis	NULL
(	NULL
a	NULL
)	NULL
,	NULL
but	NULL
it	NULL
enhances	NULL
the	NULL
survival	NULL
of	NULL
serum-starved	NULL
BJAB	NULL
cells	NULL
(	NULL
b	NULL
)	NULL
.	NULL

To	NULL
measure	NULL
the	NULL
sensitivity	NULL
of	NULL
cells	NULL
to	NULL
anti-Fas	NULL
,	NULL
approximately	NULL
20,000	NULL
cells	NULL
per	NULL
well	NULL
were	NULL
plated	NULL
in	NULL
96-well	NULL
plates	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
anti-Fas	NULL
antibody	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
protein	NULL
A	NULL
per	NULL
ml	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
surviving	NULL
cells	NULL
was	NULL
analyzed	NULL
by	NULL
MTT	NULL
assay	NULL
after	NULL
a	NULL
6-h	NULL
incubation	NULL
.	NULL

In	NULL
the	NULL
serum	NULL
starvation	NULL
assay	NULL
,	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
medium	NULL
containing	NULL
0.5	NULL
%	NULL
FCS	NULL
with	NULL
an	NULL
initial	NULL
cell	NULL
concentration	NULL
of	NULL
400,000	NULL
cells/ml	NULL
.	NULL

On	NULL
a	NULL
daily	NULL
basis	NULL
,	NULL
an	NULL
aliquot	NULL
was	NULL
tested	NULL
for	NULL
cell	NULL
viability	NULL
.	NULL

Every	NULL
second	NULL
day	NULL
the	NULL
MTT	NULL
assay	NULL
was	NULL
accompanied	NULL
by	NULL
counting	NULL
of	NULL
the	NULL
cells	NULL
in	NULL
trypan	NULL
blue	NULL
.	NULL

Cell	NULL
pools	NULL
are	NULL
as	NULL
described	NULL
for	NULL
Fig	NULL
.	NULL

6.	NULL
bation	NULL
,	NULL
all	NULL
of	NULL
the	NULL
control	NULL
cells	NULL
were	NULL
dead	NULL
whereas	NULL
10	NULL
%	NULL
of	NULL
the	NULL
BHRF1-expressing	NULL
cells	NULL
were	NULL
alive	NULL
.	NULL

The	NULL
BJAB	NULL
cells	NULL
overexpressing	NULL
Bel-2	NULL
showed	NULL
a	NULL
pattern	NULL
of	NULL
survival	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
BHRF1-transfected	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7b	NULL
)	NULL
.	NULL

DISCUSSION	NULL
This	NULL
study	NULL
was	NULL
undertaken	NULL
to	NULL
investigate	NULL
signal	NULL
transduction	NULL
pathways	NULL
involved	NULL
in	NULL
apoptosis	NULL
induced	NULL
by	NULL
cross-linking	NULL
and	NULL
activation	NULL
of	NULL
cell	NULL
surface	NULL
receptors	NULL
for	NULL
TNF	NULL
and	NULL
FasL	NULL
.	NULL

Our	NULL
first	NULL
aim	NULL
was	NULL
to	NULL
identify	NULL
gene	NULL
products	NULL
that	NULL
inhibit	NULL
this	NULL
pathway	NULL
.	NULL

By	NULL
functional	NULL
expression	NULL
cloning	NULL
,	NULL
the	NULL
EBV	NULL
early-lytic-cycle	NULL
protein	NULL
BHRF1	NULL
was	NULL
identified	NULL
as	NULL
an	NULL
antiapoptosis	NULL
protein	NULL
.	NULL

Expression	NULL
of	NULL
BHRF1	NULL
in	NULL
MCF-Fas	NULL
cells	NULL
led	NULL
to	NULL
nearly	NULL
complete	NULL
inhibition	NULL
of	NULL
cell	NULL
death	NULL
induced	NULL
by	NULL
TNF	NULL
,	NULL
anti-Fas	NULL
antibody	NULL
,	NULL
monocytes	NULL
,	NULL
and	NULL
serum	NULL
starvation	NULL
.	NULL

EBV	NULL
is	NULL
a	NULL
human	NULL
herpesvirus	NULL
with	NULL
oncogenic	NULL
potential	NULL
and	NULL
is	NULL
predominantly	NULL
associated	NULL
with	NULL
infection	NULL
of	NULL
two	NULL
target	NULL
tissues	NULL
in	NULL
vivo	NULL
:	NULL
B	NULL
lymphocytes	NULL
,	NULL
where	NULL
the	NULL
infection	NULL
is	NULL
largely	NULL
nonproduc-tive	NULL
,	NULL
and	NULL
stratified	NULL
squamous	NULL
epithelium	NULL
,	NULL
in	NULL
which	NULL
virus	NULL
repli-	NULL
voL	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
cation	NULL
occurs	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Both	NULL
cell	NULL
types	NULL
are	NULL
susceptible	NULL
to	NULL
EBV-associated	NULL
transformation	NULL
,	NULL
resulting	NULL
in	NULL
tumors	NULL
of	NULL
B-cell	NULL
origin	NULL
,	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
and	NULL
immunoblastic	NULL
lymphoma	NULL
,	NULL
or	NULL
of	NULL
epithelial	NULL
cell	NULL
origin	NULL
,	NULL
nasopharyngeal	NULL
carcinoma	NULL
and	NULL
gastric	NULL
ade-nocarcinoma	NULL
(	NULL
26	NULL
)	NULL
.	NULL

BHRF1	NULL
is	NULL
an	NULL
EBV	NULL
gene	NULL
product	NULL
of	NULL
undetermined	NULL
function	NULL
.	NULL

It	NULL
is	NULL
a	NULL
constituent	NULL
of	NULL
all	NULL
EBV	NULL
genomes	NULL
,	NULL
suggesting	NULL
that	NULL
it	NULL
has	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
viral	NULL
life	NULL
cycle	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Spliced	NULL
BHRF1	NULL
transcripts	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
latently	NULL
infected	NULL
B	NULL
cells	NULL
,	NULL
although	NULL
the	NULL
17-kDa	NULL
protein	NULL
has	NULL
yet	NULL
to	NULL
be	NULL
detected	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
35	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
the	NULL
early	NULL
phase	NULL
of	NULL
the	NULL
viral	NULL
replicative	NULL
cycle	NULL
both	NULL
BHRF1	NULL
protein	NULL
and	NULL
transcripts	NULL
are	NULL
expressed	NULL
in	NULL
abundance	NULL
(	NULL
35	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
BHRF1	NULL
is	NULL
not	NULL
required	NULL
for	NULL
viral	NULL
replication	NULL
or	NULL
B-cell	NULL
transformation	NULL
,	NULL
since	NULL
recombinant	NULL
virus	NULL
in	NULL
which	NULL
BHRF1	NULL
has	NULL
been	NULL
deleted	NULL
in	NULL
vitro	NULL
is	NULL
both	NULL
transforming	NULL
and	NULL
able	NULL
to	NULL
enter	NULL
the	NULL
replicative	NULL
cycle	NULL
(	NULL
25	NULL
)	NULL
.	NULL

These	NULL
BHRF1-negative	NULL
transformed	NULL
B	NULL
cells	NULL
express	NULL
the	NULL
full	NULL
range	NULL
of	NULL
viral	NULL
latent	NULL
gene	NULL
products	NULL
,	NULL
suggesting	NULL
an	NULL
essential	NULL
role	NULL
for	NULL
these	NULL
proteins	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
influence	NULL
of	NULL
BHRF1	NULL
,	NULL
however	NULL
,	NULL
is	NULL
much	NULL
more	NULL
likely	NULL
to	NULL
be	NULL
felt	NULL
in	NULL
the	NULL
lytic	NULL
cycle	NULL
,	NULL
in	NULL
which	NULL
the	NULL
protein	NULL
is	NULL
abundantly	NULL
expressed	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
latent	NULL
genes	NULL
is	NULL
turned	NULL
off	NULL
.	NULL

The	NULL
BHRF1	NULL
protein	NULL
of	NULL
EBV	NULL
may	NULL
be	NULL
a	NULL
structural	NULL
homolog	NULL
of	NULL
the	NULL
Bcel-2	NULL
protein	NULL
.	NULL

Alignment	NULL
of	NULL
BHRF1	NULL
and	NULL
Bel-2	NULL
has	NULL
revealed	NULL
some	NULL
25	NULL
%	NULL
amino	NULL
acid	NULL
identity	NULL
(	NULL
25	NULL
)	NULL
,	NULL
in	NULL
which	NULL
the	NULL
sequences	NULL
corresponding	NULL
to	NULL
the	NULL
BH1	NULL
,	NULL
BH2	NULL
,	NULL
and	NULL
BH3	NULL
domains	NULL
are	NULL
highly	NULL
conserved	NULL
(	NULL
7	NULL
)	NULL
.	NULL

This	NULL
and	NULL
previous	NULL
studies	NULL
indicate	NULL
that	NULL
BHRF1	NULL
is	NULL
also	NULL
functionally	NULL
related	NULL
to	NULL
Bel-2	NULL
and	NULL
the	NULL
other	NULL
family	NULL
member	NULL
,	NULL
Bcl-x	NULL
;	NULL
Previous	NULL
functional	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
ectopic	NULL
expression	NULL
of	NULL
BHRF1	NULL
can	NULL
block	NULL
apoptosis	NULL
induced	NULL
by	NULL
various	NULL
stimuli	NULL
,	NULL
such	NULL
as	NULL
withdrawal	NULL
of	NULL
serum	NULL
(	NULL
13	NULL
)	NULL
,	NULL
withdrawal	NULL
of	NULL
other	NULL
growth	NULL
factors	NULL
,	NULL
treatment	NULL
with	NULL
anticancer	NULL
agents	NULL
,	NULL
infection	NULL
with	NULL
heterologous	NULL
virus	NULL
(	NULL
45	NULL
)	NULL
,	NULL
and	NULL
ectopic	NULL
expression	NULL
of	NULL
the	NULL
tumor	NULL
suppres-sor	NULL
protein	NULL
p53	NULL
(	NULL
50	NULL
)	NULL
.	NULL

This	NULL
study	NULL
shows	NULL
that	NULL
expression	NULL
of	NULL
BHRF1	NULL
in	NULL
MCF-Fas	NULL
cells	NULL
nearly	NULL
completely	NULL
blocks	NULL
the	NULL
apoptotic	NULL
pathway	NULL
induced	NULL
by	NULL
TNF	NULL
or	NULL
anti-Fas	NULL
even	NULL
in	NULL
long-term	NULL
assays	NULL
with	NULL
high	NULL
concentrations	NULL
of	NULL
effector	NULL
molecules	NULL
.	NULL

Moreover	NULL
,	NULL
we	NULL
show	NULL
that	NULL
expression	NULL
of	NULL
BHRF1	NULL
protects	NULL
MCF-Fas	NULL
cells	NULL
from	NULL
monocyte-mediated	NULL
killing	NULL
in	NULL
a	NULL
manner	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
Bel-2	NULL
and	NULL
Bcel-x	NULL
,	NULL
,	NULL
.	NULL

TNF	NULL
is	NULL
the	NULL
major	NULL
mediator	NULL
of	NULL
cell	NULL
death	NULL
used	NULL
by	NULL
monocytes	NULL
(	NULL
1	NULL
,	NULL
19	NULL
)	NULL
;	NULL
thus	NULL
,	NULL
this	NULL
result	NULL
emphasizes	NULL
the	NULL
protective	NULL
effect	NULL
of	NULL
BHRF1	NULL
against	NULL
this	NULL
cytokine	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
BHRFI1	NULL
to	NULL
protect	NULL
epithelial	NULL
cells	NULL
from	NULL
TNF-	NULL
and	NULL
anti-Fas-mediated	NULL
apoptosis	NULL
is	NULL
supported	NULL
by	NULL
a	NULL
recent	NULL
publication	NULL
showing	NULL
that	NULL
expression	NULL
of	NULL
BHRF1	NULL
protected	NULL
407	NULL
intestinal	NULL
epithelial	NULL
cells	NULL
against	NULL
apoptosis	NULL
induced	NULL
by	NULL
combination	NULL
of	NULL
cycloheximide	NULL
and	NULL
TNF	NULL
or	NULL
anti-Fas	NULL
antibody	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
BHRF1	NULL
may	NULL
,	NULL
like	NULL
Bcel-2	NULL
in	NULL
epithelial	NULL
cells	NULL
,	NULL
be	NULL
a	NULL
general	NULL
inhibitor	NULL
of	NULL
apoptosis	NULL
,	NULL
acting	NULL
at	NULL
a	NULL
point	NULL
at	NULL
which	NULL
the	NULL
different	NULL
signaling	NULL
pathways	NULL
converge	NULL
into	NULL
a	NULL
common	NULL
apoptotic	NULL
pathway	NULL
.	NULL

Surprisingly	NULL
,	NULL
however	NULL
,	NULL
expression	NULL
of	NULL
BHRF1	NULL
or	NULL
overexpression	NULL
of	NULL
Bel-2	NULL
did	NULL
not	NULL
protect	NULL
BJAB	NULL
cells	NULL
from	NULL
anti-Fas-mediated	NULL
apoptosis	NULL
.	NULL

BHRF1	NULL
and	NULL
Bel-2	NULL
did	NULL
,	NULL
however	NULL
,	NULL
increase	NULL
the	NULL
survival	NULL
of	NULL
BJAB	NULL
cells	NULL
deprived	NULL
of	NULL
serum	NULL
.	NULL

Two	NULL
other	NULL
groups	NULL
have	NULL
obtained	NULL
similar	NULL
results	NULL
with	NULL
Bel-2	NULL
in	NULL
lymphocytes	NULL
:	NULL
overexpression	NULL
of	NULL
Bel-2	NULL
protected	NULL
lymphocytes	NULL
from	NULL
gamma	NULL
radiation	NULL
,	NULL
staurosporine	NULL
,	NULL
and	NULL
serum	NULL
deprivation	NULL
but	NULL
not	NULL
from	NULL
anti-Fas-mediated	NULL
apoptosis	NULL
(	NULL
5	NULL
,	NULL
41	NULL
)	NULL
.	NULL

Those	NULL
authors	NULL
raised	NULL
the	NULL
possibility	NULL
that	NULL
Bel-2	NULL
and	NULL
anti-Fas	NULL
may	NULL
regulate	NULL
distinct	NULL
pathways	NULL
to	NULL
apoptosis	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
however	NULL
,	NULL
a	NULL
recent	NULL
study	NULL
shows	NULL
very	NULL
clearly	NULL
that	NULL
overexpression	NULL
of	NULL
Bel-2	NULL
inhibits	NULL
Fas-induced	NULL
activation	NULL
of	NULL
caspase-3/CPP32	NULL
and	NULL
apoptosis	NULL
in	NULL
lymphocytes	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Our	NULL
present	NULL
and	NULL
previous	NULL
results	NULL
(	NULL
17	NULL
)	NULL
showing	NULL
complete	NULL
inhibition	NULL
of	NULL
anti-Fas-mediated	NULL
apoptosis	NULL
by	NULL
BHRF1	NULL
,	NULL
Bel-2	NULL
,	NULL
and	NULL
Bcl-x	NULL
,	NULL
in	NULL
MCF-Fas	NULL
cells	NULL
suggest	NULL
that	NULL
these	NULL
proteins	NULL
can	NULL
regulate	NULL
Fas	NULL
BHRFI	NULL
AND	NULL
APOPTOSIS	NULL
-	NULL
7515	NULL
induced	NULL
apoptosis	NULL
but	NULL
that	NULL
their	NULL
effect	NULL
upon	NULL
it	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
cell	NULL
type	NULL
.	NULL

The	NULL
different	NULL
results	NULL
obtained	NULL
with	NULL
MCF-Fas	NULL
and	NULL
BJAB	NULL
cells	NULL
may	NULL
be	NULL
explained	NULL
through	NULL
different	NULL
expression	NULL
levels	NULL
of	NULL
positive	NULL
and	NULL
negative	NULL
regulators	NULL
of	NULL
apoptosis	NULL
.	NULL

The	NULL
protective	NULL
effect	NULL
seen	NULL
in	NULL
the	NULL
MCF-Fas	NULL
cells	NULL
may	NULL
be	NULL
due	NULL
to	NULL
the	NULL
high	NULL
expression	NULL
levels	NULL
of	NULL
BHRF1	NULL
,	NULL
which	NULL
can	NULL
overcome	NULL
and	NULL
prevent	NULL
homodimerization	NULL
between	NULL
preexisting	NULL
low	NULL
levels	NULL
of	NULL
death-promoting	NULL
proteins	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
expression	NULL
levels	NULL
of	NULL
BHRF1	NULL
or	NULL
Bcel-2	NULL
in	NULL
BJAB	NULL
cells	NULL
may	NULL
be	NULL
too	NULL
low	NULL
to	NULL
prevent	NULL
homodimerization	NULL
of	NULL
a	NULL
high	NULL
level	NULL
of	NULL
preexisting	NULL
positive	NULL
regu-lators	NULL
.	NULL

But	NULL
why	NULL
then	NULL
do	NULL
we	NULL
see	NULL
an	NULL
effect	NULL
by	NULL
BHRF1	NULL
and	NULL
Bel-2	NULL
in	NULL
serum	NULL
starvation	NULL
of	NULL
BJAB	NULL
cells	NULL
?	NULL

This	NULL
difference	NULL
might	NULL
be	NULL
explained	NULL
by	NULL
the	NULL
strength	NULL
of	NULL
the	NULL
given	NULL
stimuli	NULL
.	NULL

The	NULL
anti-Fas	NULL
stimulus	NULL
in	NULL
BJAB	NULL
cells	NULL
is	NULL
very	NULL
strong	NULL
,	NULL
resulting	NULL
in	NULL
complete	NULL
killing	NULL
of	NULL
target	NULL
cells	NULL
in	NULL
6	NULL
h	NULL
,	NULL
whereas	NULL
withdrawal	NULL
of	NULL
growth	NULL
factors	NULL
is	NULL
a	NULL
weak	NULL
death	NULL
stimulus	NULL
,	NULL
with	NULL
killing	NULL
taking	NULL
several	NULL
days	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
note	NULL
that	NULL
anti-Fas-induced	NULL
cell	NULL
death	NULL
in	NULL
MCF-Fas	NULL
cells	NULL
takes	NULL
24	NULL
to	NULL
48	NULL
h.	NULL
Thus	NULL
,	NULL
one	NULL
possibility	NULL
is	NULL
that	NULL
the	NULL
Fas-induced	NULL
death	NULL
signal	NULL
in	NULL
BJAB	NULL
cells	NULL
is	NULL
so	NULL
strong	NULL
that	NULL
it	NULL
breaks	NULL
through	NULL
the	NULL
checkpoint	NULL
regulated	NULL
by	NULL
the	NULL
Bcl-2	NULL
family	NULL
.	NULL

Contrary	NULL
to	NULL
monocyte-mediated	NULL
killing	NULL
,	NULL
BHRF1	NULL
,	NULL
Bel-2	NULL
,	NULL
or	NULL
Bcl-x	NULL
,	NULL
,	NULL
expression	NULL
did	NULL
not	NULL
protect	NULL
MCF-Fas	NULL
cells	NULL
from	NULL
LAK-cell-mediated	NULL
killing	NULL
.	NULL

Recent	NULL
results	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
perforin-granzyme	NULL
B-mediated	NULL
and	NULL
Fas-mediated	NULL
pathways	NULL
are	NULL
the	NULL
two	NULL
most	NULL
important	NULL
mechanisms	NULL
used	NULL
by	NULL
LAK	NULL
cells	NULL
in	NULL
mediating	NULL
cytotoxicity	NULL
(	NULL
39	NULL
,	NULL
53	NULL
)	NULL
.	NULL

As	NULL
anti-Fas	NULL
killing	NULL
takes	NULL
24	NULL
to	NULL
48	NULL
h	NULL
,	NULL
and	NULL
as	NULL
BHRF1	NULL
,	NULL
Bel-2	NULL
,	NULL
and	NULL
Bel-x	NULL
,	NULL
,	NULL
protected	NULL
MCF-Fas	NULL
cells	NULL
from	NULL
anti-Fas-mediated	NULL
apoptosis	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
the	NULL
killing	NULL
of	NULL
MCF-Fas	NULL
cells	NULL
by	NULL
LAK	NULL
cells	NULL
in	NULL
the	NULL
4-h	NULL
assay	NULL
was	NULL
mediated	NULL
through	NULL
the	NULL
perforin-granzyme	NULL
B	NULL
pathway	NULL
.	NULL

In	NULL
the	NULL
perforin-granzyme	NULL
B	NULL
pathway	NULL
,	NULL
the	NULL
LAK	NULL
cells	NULL
deliver	NULL
lethal	NULL
hits	NULL
by	NULL
releasing	NULL
their	NULL
granule	NULL
contents	NULL
after	NULL
binding	NULL
to	NULL
the	NULL
target	NULL
cell	NULL
.	NULL

The	NULL
inability	NULL
of	NULL
BHRF1	NULL
,	NULL
Bel-2	NULL
,	NULL
or	NULL
Bel-x	NULL
,	NULL
,	NULL
to	NULL
protect	NULL
MCF-Fas	NULL
from	NULL
perforin-granzyme	NULL
B-mediated	NULL
cell	NULL
death	NULL
may	NULL
be	NULL
explained	NULL
in	NULL
one	NULL
of	NULL
two	NULL
ways	NULL
.	NULL

Pores	NULL
formed	NULL
by	NULL
perforin	NULL
may	NULL
induce	NULL
a	NULL
loss	NULL
of	NULL
cell	NULL
membrane	NULL
integrity	NULL
,	NULL
which	NULL
may	NULL
result	NULL
in	NULL
a	NULL
necrotic	NULL
form	NULL
of	NULL
cell	NULL
death	NULL
unpreventable	NULL
by	NULL
BHRF1	NULL
,	NULL
Bel-2	NULL
,	NULL
or	NULL
Bcl-x	NULL
,	NULL
or	NULL
the	NULL
entrance	NULL
of	NULL
granzyme	NULL
B	NULL
to	NULL
the	NULL
cell	NULL
may	NULL
be	NULL
responsible	NULL
for	NULL
induction	NULL
of	NULL
apoptosis	NULL
and	NULL
bypass	NULL
the	NULL
otherwise	NULL
protective	NULL
effect	NULL
of	NULL
BHRF1	NULL
,	NULL
Bel-2	NULL
,	NULL
or	NULL
Bel-x	NULL
,	NULL
.	NULL

Apoptosis	NULL
induced	NULL
by	NULL
granzyme	NULL
B	NULL
can	NULL
not	NULL
be	NULL
inhibited	NULL
by	NULL
Bel-2	NULL
,	NULL
and	NULL
recent	NULL
findings	NULL
suggest	NULL
that	NULL
granzyme	NULL
B-induced	NULL
cell	NULL
death	NULL
occurs	NULL
via	NULL
direct	NULL
activation	NULL
of	NULL
downstream	NULL
caspases	NULL
,	NULL
thus	NULL
bypassing	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
the	NULL
Bel-2	NULL
family	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
show	NULL
that	NULL
BHRF1	NULL
,	NULL
Bel-2	NULL
,	NULL
and	NULL
Bcl-x	NULL
,	NULL
are	NULL
able	NULL
to	NULL
inhibit	NULL
cyto-kine-induced	NULL
activation	NULL
of	NULL
caspase-3/CPP32	NULL
,	NULL
making	NULL
the	NULL
latter	NULL
hypothesis	NULL
possible	NULL
.	NULL

Several	NULL
lines	NULL
of	NULL
evidence	NULL
suggest	NULL
the	NULL
involvement	NULL
of	NULL
cPLA	NULL
;	NULL
in	NULL
the	NULL
cytotoxic	NULL
pathway	NULL
of	NULL
TNF	NULL
and	NULL
Fas	NULL
(	NULL
11	NULL
,	NULL
17	NULL
,	NULL
32	NULL
,	NULL
52	NULL
,	NULL
58	NULL
)	NULL
.	NULL

This	NULL
idea	NULL
is	NULL
further	NULL
supported	NULL
by	NULL
our	NULL
data	NULL
showing	NULL
that	NULL
expression	NULL
of	NULL
BHRF1	NULL
inhibited	NULL
the	NULL
activation	NULL
of	NULL
cPLA	NULL
;	NULL
by	NULL
TNF	NULL
and	NULL
anti-Fas	NULL
in	NULL
a	NULL
manner	NULL
that	NULL
paralleled	NULL
their	NULL
ability	NULL
to	NULL
inhibit	NULL
cell	NULL
death	NULL
.	NULL

Interestingly	NULL
,	NULL
other	NULL
inhibitors	NULL
of	NULL
TNF-induced	NULL
apoptosis	NULL
,	NULL
such	NULL
as	NULL
heat	NULL
shock	NULL
protein	NULL
70	NULL
,	NULL
Bel-2	NULL
,	NULL
and	NULL
Bcl-x	NULL
,	NULL
,	NULL
also	NULL
inhibit	NULL
TNF-induced	NULL
activation	NULL
of	NULL
cPLA	NULL
,	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Activated	NULL
cPLA	NULL
,	NULL
releases	NULL
arachidonic	NULL
acid	NULL
from	NULL
the	NULL
s	NULL
»	NULL
-2	NULL
position	NULL
of	NULL
phospho-lipids	NULL
,	NULL
which	NULL
provides	NULL
a	NULL
source	NULL
for	NULL
the	NULL
production	NULL
of	NULL
biologically	NULL
active	NULL
lipid	NULL
mediators	NULL
such	NULL
as	NULL
prostaglandins	NULL
and	NULL
leuko-trienes	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
BHRF1	NULL
may	NULL
,	NULL
through	NULL
its	NULL
inhibition	NULL
of	NULL
cPLA	NULL
;	NULL
,	NULL
also	NULL
act	NULL
as	NULL
an	NULL
anti-inflammatory	NULL
factor	NULL
.	NULL

A	NULL
putative	NULL
function	NULL
of	NULL
BHRFI1	NULL
could	NULL
be	NULL
to	NULL
protect	NULL
EBV-infected	NULL
epithelial	NULL
cells	NULL
from	NULL
TNF-	NULL
and/or	NULL
Fas-induced	NULL
cell	NULL
death	NULL
in	NULL
order	NULL
to	NULL
maximize	NULL
virus	NULL
production	NULL
.	NULL

Both	NULL
TNF	NULL
and	NULL
Fas	NULL
exhibit	NULL
antiviral	NULL
activity	NULL
and	NULL
may	NULL
be	NULL
two	NULL
components	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
's	NULL
response	NULL
to	NULL
viral	NULL
infection	NULL
.	NULL

Another	NULL
putative	NULL
role	NULL
of	NULL
BHRF1	NULL
may	NULL
be	NULL
inhibition	NULL
of	NULL
apoptosis	NULL
during	NULL
malig-	NULL
7516	NULL
FOGHSGAARD	NULL
AND	NULL
JAATTELA	NULL
nant	NULL
transformation	NULL
of	NULL
infected	NULL
cells	NULL
.	NULL

Although	NULL
BHRF1	NULL
(	NULL
like	NULL
Bcl-2	NULL
)	NULL
alone	NULL
is	NULL
insufficient	NULL
to	NULL
cause	NULL
transformation	NULL
,	NULL
the	NULL
surviving	NULL
cells	NULL
could	NULL
provide	NULL
the	NULL
substrate	NULL
for	NULL
further	NULL
genetic	NULL
changes	NULL
in	NULL
conventional	NULL
oncogenes	NULL
such	NULL
as	NULL
c-myc	NULL
.	NULL

The	NULL
role	NULL
of	NULL
BHRF1	NULL
in	NULL
EBV-infected	NULL
lymphoid	NULL
cells	NULL
remains	NULL
unclear	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Manuel	NULL
Buchwald	NULL
(	NULL
University	NULL
of	NULL
Toronto	NULL
,	NULL
Toronto	NULL
,	NULL
On-tario	NULL
,	NULL
Canada	NULL
)	NULL
for	NULL
the	NULL
pREP-cDNA	NULL
library	NULL
and	NULL
pREP-BGal	NULL
plasmid	NULL
,	NULL
Peter	NULL
Krammer	NULL
(	NULL
German	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
Heidelberg	NULL
,	NULL
Ger-many	NULL
)	NULL
for	NULL
anti-APO-1	NULL
antibody	NULL
,	NULL
Gabriel	NULL
Nufiez	NULL
(	NULL
University	NULL
of	NULL
Michi-gan	NULL
,	NULL
Ann	NULL
Arbor	NULL
)	NULL
for	NULL
anti-Bcl-2	NULL
antibody	NULL
,	NULL
and	NULL
Guy	NULL
G.	NULL
Poirier	NULL
(	NULL
Univer-sité	NULL
Laval	NULL
Research	NULL
Center	NULL
,	NULL
Laval	NULL
,	NULL
Quebec	NULL
,	NULL
Canada	NULL
)	NULL
for	NULL
anti-PARP	NULL
antibody	NULL
.	NULL

The	NULL
excellent	NULL
technical	NULL
assistance	NULL
provided	NULL
by	NULL
Helle	NULL
Mourit-zen	NULL
is	NULL
acknowledged	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Danish	NULL
Cancer	NULL
Society	NULL
,	NULL
the	NULL
Novo	NULL
Nordisk	NULL
Foundation	NULL
,	NULL
the	NULL
Danish	NULL
Medical	NULL
Research	NULL
Council	NULL
,	NULL
the	NULL
Bernhard	NULL
and	NULL
Meta	NULL
Rasmussen	NULL
Foundation	NULL
,	NULL
the	NULL
Jeppe	NULL
and	NULL
Ovita	NULL
Juhl	NULL
Foundation	NULL
,	NULL
and	NULL
the	NULL
Astrid	NULL
Thaysen	NULL
Foundation	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Adams	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
C.	NULL
F.	NULL
Nathan	NULL
.	NULL

1983	NULL
.	NULL

Molecular	NULL
mechanisms	NULL
in	NULL
tumor	NULL
cell	NULL
killing	NULL
by	NULL
activated	NULL
macrophages	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
4:166-170	NULL
.	NULL

2	NULL
.	NULL

Armstrong	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
T.	NULL
Aja	NULL
,	NULL
J.	NULL
Xiang	NULL
,	NULL
S.	NULL
Gaur	NULL
,	NULL
J.	NULL
F.	NULL
Krebs	NULL
,	NULL
K.	NULL
Hoang	NULL
,	NULL
X.	NULL
Bai	NULL
,	NULL
S.	NULL
J.	NULL
Korsmeyer	NULL
,	NULL
D.	NULL
S.	NULL
Karanewsky	NULL
,	NULL
L.	NULL
C.	NULL
Fritz	NULL
,	NULL
and	NULL
K.	NULL
J.	NULL
Tomaselli	NULL
,	NULL
1996	NULL
.	NULL

Fas-induced	NULL
activation	NULL
of	NULL
the	NULL
cell	NULL
death-related	NULL
protease	NULL
CPP32	NULL
is	NULL
inhibited	NULL
by	NULL
Bcl-2	NULL
and	NULL
by	NULL
ICE	NULL
family	NULL
protease	NULL
inhibitors	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:16850-16855	NULL
.	NULL

3	NULL
.	NULL

Beidler	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
M.	NULL
Tewari	NULL
,	NULL
P.	NULL
D.	NULL
Friesen	NULL
,	NULL
G.	NULL
Poirier	NULL
,	NULL
and	NULL
V.	NULL
M.	NULL
Dixit	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
baculovirus	NULL
p35	NULL
protein	NULL
inhibits	NULL
Fas-	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor-induced	NULL
apoptosis	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:16526-16528	NULL
.	NULL

4	NULL
.	NULL

Bump	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
M.	NULL
Hackett	NULL
,	NULL
M.	NULL
Hugunin	NULL
,	NULL
S.	NULL
Seshagiri	NULL
,	NULL
K.	NULL
Brady	NULL
,	NULL
P.	NULL
Chen	NULL
,	NULL
C.	NULL
Ferenz	NULL
,	NULL
S.	NULL
Franklin	NULL
,	NULL
T.	NULL
Gbayur	NULL
,	NULL
P.	NULL
Li	NULL
,	NULL
P.	NULL
Licari	NULL
,	NULL
J.	NULL
Mankovich	NULL
,	NULL
L.	NULL
Shi	NULL
,	NULL
A.	NULL
H.	NULL
Greenberg	NULL
,	NULL
L.	NULL
K.	NULL
Miller	NULL
,	NULL
and	NULL
W.	NULL
W.	NULL
Wong	NULL
.	NULL

1995	NULL
.	NULL

Inhibition	NULL
of	NULL
ICE	NULL
family	NULL
proteases	NULL
by	NULL
baculovirus	NULL
antiapoptotic	NULL
protein	NULL
p35	NULL
.	NULL

Science	NULL
269:1885-1888	NULL
.	NULL

5	NULL
.	NULL

Chinnaiyan	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
K.	NULL
Orth	NULL
,	NULL
K.	NULL
O'Rourke	NULL
,	NULL
H.	NULL
Duan	NULL
,	NULL
G.	NULL
G.	NULL
Poirier	NULL
,	NULL
and	NULL
V.	NULL
M.	NULL
Dixit	NULL
.	NULL

1996	NULL
.	NULL

Molecular	NULL
ordering	NULL
of	NULL
the	NULL
cell	NULL
death	NULL
pathway	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:4573-4576	NULL
.	NULL

6	NULL
.	NULL

Darmon	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
D.	NULL
W.	NULL
Nicholson	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Bleackley	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
apoptotic	NULL
protease	NULL
CPP32	NULL
by	NULL
cytotoxic	NULL
T-cell-derived	NULL
granzyme	NULL
B	NULL
.	NULL

Nature	NULL
377:446-448	NULL
.	NULL

7	NULL
.	NULL

D'Sa-Eipper	NULL
,	NULL
C.	NULL
,	NULL
T.	NULL
Subramanian	NULL
,	NULL
and	NULL
G.	NULL
Chinnadurai	NULL
.	NULL

1996.	NULL
bfl-1	NULL
,	NULL
a	NULL
bel-2	NULL
homologue	NULL
,	NULL
suppresses	NULL
p53-induced	NULL
apoptosis	NULL
and	NULL
exhibits	NULL
potent	NULL
cooperative	NULL
transforming	NULL
activity	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

56:3879-3882	NULL
.	NULL

8	NULL
.	NULL

Duan	NULL
,	NULL
H.	NULL
,	NULL
A.	NULL
M.	NULL
Chinnaiyan	NULL
,	NULL
P.	NULL
L.	NULL
Hudson	NULL
,	NULL
J.	NULL
P.	NULL
Wing	NULL
,	NULL
W.-W	NULL
.	NULL

He	NULL
,	NULL
and	NULL
V.	NULL
M.	NULL
Dixit	NULL
.	NULL

1996	NULL
.	NULL

ICE-LAP3	NULL
,	NULL
a	NULL
novel	NULL
mammalian	NULL
homologue	NULL
of	NULL
the	NULL
Caenorhab-ditis	NULL
elegans	NULL
cell	NULL
death	NULL
protein	NULL
ced-3	NULL
is	NULL
activated	NULL
during	NULL
Fas-	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor-induced	NULL
apoptosis	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:1621-1625	NULL
.	NULL

9	NULL
.	NULL

Enari	NULL
,	NULL
M.	NULL
,	NULL
H.	NULL
Hug	NULL
,	NULL
and	NULL
S.	NULL
Nagata	NULL
.	NULL

1995	NULL
.	NULL

Involvement	NULL
of	NULL
an	NULL
ICE-like	NULL
protease	NULL
in	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

Nature	NULL
375:78-81	NULL
.	NULL

10	NULL
.	NULL

Gooding	NULL
,	NULL
L.	NULL
R.	NULL
,	NULL
L.	NULL
W.	NULL
Elmore	NULL
,	NULL
A.	NULL
E.	NULL
Tollefson	NULL
,	NULL
H.	NULL
A.	NULL
Brady	NULL
,	NULL
and	NULL
W.	NULL
S.	NULL
M.	NULL
Wold	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
14,700	NULL
MW	NULL
protein	NULL
from	NULL
E3	NULL
region	NULL
of	NULL
adenovirus	NULL
inhibits	NULL
cytolysis	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

Cell	NULL
53:341-346	NULL
.	NULL

11	NULL
.	NULL

Hayakawa	NULL
,	NULL
M.	NULL
,	NULL
N.	NULL
Ishida	NULL
,	NULL
K.	NULL
Takeuchi	NULL
,	NULL
S.	NULL
Shibamoto	NULL
,	NULL
T.	NULL
Hori	NULL
,	NULL
N.	NULL
Oku	NULL
,	NULL
F.	NULL
Ito	NULL
,	NULL
and	NULL
M.	NULL
Tsujimoto	NULL
.	NULL

1993	NULL
.	NULL

Arachidonic	NULL
acid-selective	NULL
cytosolic	NULL
phospholipase	NULL
A2	NULL
is	NULL
crucial	NULL
in	NULL
the	NULL
cytotoxic	NULL
action	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:11290-11295	NULL
.	NULL

12	NULL
.	NULL

Heller	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
and	NULL
M.	NULL
Kronke	NULL
.	NULL

1994	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
receptor-medi-ated	NULL
signalling	NULL
pathways	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

126:5-9	NULL
.	NULL

13	NULL
.	NULL

Henderson	NULL
,	NULL
S.	NULL
,	NULL
D.	NULL
Huen	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
C.	NULL
Dawson	NULL
,	NULL
G.	NULL
Johnson	NULL
,	NULL
and	NULL
A.	NULL
Rickin-son	NULL
.	NULL

1993	NULL
.	NULL

Epstein-Barr	NULL
virus-coded	NULL
BHRF1	NULL
protein	NULL
,	NULL
a	NULL
viral	NULL
homologue	NULL
of	NULL
bel-2	NULL
,	NULL
protects	NULL
B	NULL
cells	NULL
from	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:8479-8483	NULL
.	NULL

14	NULL
.	NULL

Hirt	NULL
,	NULL
B	NULL
.	NULL

1967	NULL
.	NULL

Selective	NULL
extraction	NULL
of	NULL
polyoma	NULL
DNA	NULL
from	NULL
infected	NULL
mouse	NULL
cell	NULL
cultures	NULL
.	NULL

J.	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

26:365-369	NULL
.	NULL

15	NULL
.	NULL

Itoh	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
S.	NULL
Nagata	NULL
.	NULL

1993	NULL
.	NULL

A	NULL
novel	NULL
protein	NULL
domain	NULL
required	NULL
for	NULL
apoptosis	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:10932-10937	NULL
.	NULL

16	NULL
.	NULL

M.	NULL
1993	NULL
.	NULL

Overexpression	NULL
of	NULL
major	NULL
heat	NULL
shock	NULL
protein	NULL
hsp70	NULL
inhibits	NULL
TNF-induced	NULL
activation	NULL
of	NULL
phospholipase	NULL
A	NULL
;	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:4286-4294	NULL
.	NULL

17	NULL
.	NULL

M.	NULL
,	NULL
M.	NULL
Benedict	NULL
,	NULL
M.	NULL
Tewari	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Shayman	NULL
,	NULL
and	NULL
V.	NULL
M.	NULL
Dixit	NULL
.	NULL

1995	NULL
.	NULL

Bcl-x	NULL
and	NULL
Bel-2	NULL
inhibit	NULL
TNF	NULL
and	NULL
Fas-induced	NULL
apoptosis	NULL
and	NULL
activation	NULL
of	NULL
phospholipase	NULL
A	NULL
;	NULL
in	NULL
breast	NULL
carcinoma	NULL
cells	NULL
.	NULL

Oncogene	NULL
10:2297-2305	NULL
.	NULL

18	NULL
.	NULL

Jiiitteli	NULL
,	NULL
M.	NULL
,	NULL
H.	NULL
Mourizen	NULL
,	NULL
F.	NULL
Elling	NULL
,	NULL
and	NULL
L.	NULL
Bastholm	NULL
.	NULL

1996	NULL
.	NULL

A20	NULL
zinc	NULL
finger	NULL
protein	NULL
inhibits	NULL
TNF	NULL
and	NULL
IL-1	NULL
signaling	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

156:1166-1173	NULL
.	NULL

19	NULL
.	NULL

M.	NULL
,	NULL
and	NULL
D.	NULL
Wissing	NULL
.	NULL

1993	NULL
.	NULL

Heat	NULL
shock	NULL
proteins	NULL
protect	NULL
cells	NULL
from	NULL
monocyte	NULL
cytotoxicity	NULL
:	NULL
possible	NULL
mechanism	NULL
of	NULL
self-protection	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

177:231-236	NULL
.	NULL

20	NULL
.	NULL

Kawanishi	NULL
,	NULL
M.	NULL
1997	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
BHRF1	NULL
protein	NULL
protects	NULL
intestine	NULL
21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30.	NULL
.	NULL

Nagata	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
P.	NULL
Golstein	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
Fas	NULL
death	NULL
factor	NULL
.	NULL

Science	NULL
267:1449-	NULL
32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

J.	NULL
Viror	NULL
.	NULL

407	NULL
epithelial	NULL
cells	NULL
from	NULL
apoptosis	NULL
induced	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
and	NULL
anti-Fas	NULL
antibody	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

71:3319-3322	NULL
.	NULL

Kieff	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
D.	NULL
Liebowitz	NULL
.	NULL

1990	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
and	NULL
its	NULL
replication	NULL
,	NULL
p.	NULL
1889-1920	NULL
.	NULL

In	NULL
B.	NULL
N.	NULL
Fields	NULL
et	NULL
al	NULL
.	NULL

(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Fields	NULL
virology	NULL
,	NULL
2nd	NULL
ed	NULL
.	NULL

Raven	NULL
,	NULL
New	NULL
York	NULL
,	NULL
N.Y.	NULL
Krasnow	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
L.	NULL
Zhang	NULL
,	NULL
K.	NULL
Leung	NULL
,	NULL
L.	NULL
Osborn	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1991	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor-alpha	NULL
,	NULL
interleukin	NULL
1	NULL
,	NULL
and	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
are	NULL
independent	NULL
activators	NULL
of	NULL
NF-kappa	NULL
B	NULL
which	NULL
differentially	NULL
activate	NULL
T	NULL
cells	NULL
.	NULL

Cytokine	NULL
3:372-379	NULL
.	NULL

Laemmli	NULL
,	NULL
U.	NULL
K.	NULL
1970	NULL
.	NULL

Cleavage	NULL
of	NULL
structural	NULL
proteins	NULL
during	NULL
the	NULL
assembly	NULL
of	NULL
the	NULL
head	NULL
of	NULL
bacteriophage	NULL
T4	NULL
.	NULL

Nature	NULL
227:680-685	NULL
.	NULL

Los	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Van	NULL
de	NULL
Craen	NULL
,	NULL
L.	NULL
C.	NULL
Penning	NULL
,	NULL
H.	NULL
Schenk	NULL
,	NULL
M.	NULL
Westendorp	NULL
,	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
,	NULL
W.	NULL
Drige	NULL
,	NULL
P.	NULL
H.	NULL
Krammer	NULL
,	NULL
W.	NULL
Fiers	NULL
,	NULL
and	NULL
K.	NULL
Schultze-Osthoff	NULL
.	NULL

1995	NULL
.	NULL

Requirement	NULL
of	NULL
an	NULL
ICE/CED-3	NULL
protease	NULL
for	NULL
Fas/Apo-1-mediated	NULL
apoptosis	NULL
.	NULL

Nature	NULL
375:81-83.	NULL
.	NULL

Marchini	NULL
,	NULL
A.	NULL
,	NULL
B.	NULL
Tomkinson	NULL
,	NULL
J.	NULL
I.	NULL
Cohen	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1991	NULL
.	NULL

BHRF1	NULL
,	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
gene	NULL
with	NULL
homology	NULL
to	NULL
Bel2	NULL
,	NULL
is	NULL
dispensable	NULL
for	NULL
B-lym-phocyte	NULL
transformation	NULL
and	NULL
virus	NULL
replication	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:5991-6000	NULL
.	NULL

Miller	NULL
,	NULL
G.	NULL
1990	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
:	NULL
biology	NULL
,	NULL
pathogenesis	NULL
,	NULL
and	NULL
medical	NULL
as-pects	NULL
,	NULL
p.	NULL
1921-1958	NULL
.	NULL

In	NULL
B.	NULL
N.	NULL
Fields	NULL
et	NULL
al	NULL
.	NULL

(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Fields	NULL
virology	NULL
,	NULL
2nd	NULL
ed	NULL
.	NULL

Raven	NULL
,	NULL
New	NULL
York	NULL
,	NULL
N.Y.	NULL
Miura	NULL
,	NULL
M.	NULL
,	NULL
H.	NULL
Zhu	NULL
,	NULL
R.	NULL
Rotello	NULL
,	NULL
E.	NULL
A.	NULL
Hartwieg	NULL
,	NULL
and	NULL
J.	NULL
Yuan	NULL
.	NULL

1993	NULL
.	NULL

Induction	NULL
of	NULL
apoptosis	NULL
in	NULL
fibroblasts	NULL
by	NULL
IL-1B-converting	NULL
enzyme	NULL
,	NULL
a	NULL
mammalian	NULL
homolog	NULL
of	NULL
the	NULL
C.	NULL
elegans	NULL
cell	NULL
death	NULL
gene	NULL
ced-3	NULL
.	NULL

Cell	NULL
75:653-660	NULL
.	NULL

Mosmann	NULL
,	NULL
T.	NULL
1983	NULL
.	NULL

Rapid	NULL
colorimetric	NULL
assay	NULL
for	NULL
cellular	NULL
growth	NULL
and	NULL
survival	NULL
:	NULL
application	NULL
to	NULL
proliferation	NULL
and	NULL
cytotoxicity	NULL
assays	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
65:55-63	NULL
.	NULL

Muzio	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
M.	NULL
Chinnaiyan	NULL
,	NULL
F.	NULL
C.	NULL
Kischkel	NULL
,	NULL
K.	NULL
O'Rourke	NULL
,	NULL
A.	NULL
Shevchenko	NULL
,	NULL
J.	NULL
Ni	NULL
,	NULL
C.	NULL
Scaffidi	NULL
,	NULL
J.	NULL
D.	NULL
Bretz	NULL
,	NULL
M.	NULL
Zhang	NULL
,	NULL
R.	NULL
Gentz	NULL
,	NULL
M.	NULL
Mann	NULL
,	NULL
P.	NULL
H.	NULL
Krammer	NULL
,	NULL
M.	NULL
E.	NULL
Peter	NULL
,	NULL
and	NULL
V.	NULL
M.	NULL
Dixit	NULL
.	NULL

1996	NULL
.	NULL

FLICE	NULL
,	NULL
a	NULL
novel	NULL
FADD-homologous	NULL
ICE/CED-3-like	NULL
protease	NULL
,	NULL
is	NULL
recruited	NULL
to	NULL
CD95	NULL
(	NULL
Fas/APO-1	NULL
)	NULL
death-inducing	NULL
signaling	NULL
complex	NULL
.	NULL

Cell	NULL
85:817-827	NULL
.	NULL

Nagata	NULL
,	NULL
S.	NULL
1997	NULL
.	NULL

Apoptosis	NULL
by	NULL
death	NULL
factor	NULL
.	NULL

Cell	NULL
88:355-365	NULL
.	NULL

1456	NULL
.	NULL

Neale	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
A.	NULL
Fiera	NULL
,	NULL
and	NULL
N.	NULL
Matthews	NULL
.	NULL

1988	NULL
.	NULL

Involvement	NULL
of	NULL
phospholipase	NULL
A	NULL
;	NULL
activation	NULL
in	NULL
tumour	NULL
cell	NULL
killing	NULL
by	NULL
tumour	NULL
necrosis	NULL
factor	NULL
.	NULL

Immunology	NULL
64:81-85	NULL
.	NULL

Nicholson	NULL
,	NULL
D.	NULL
W.	NULL
1996	NULL
.	NULL

ICE/CED3-like	NULL
proteases	NULL
as	NULL
therapeutic	NULL
targets	NULL
for	NULL
the	NULL
control	NULL
of	NULL
inappropriate	NULL
apoptosis	NULL
.	NULL

Nat	NULL
.	NULL

Biotechnol	NULL
.	NULL

14:297-301	NULL
.	NULL

Oltvai	NULL
,	NULL
Z.	NULL
N.	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Korsmeyer	NULL
.	NULL

1994	NULL
.	NULL

Checkpoints	NULL
of	NULL
dueling	NULL
dimers	NULL
foil	NULL
death	NULL
wishes	NULL
.	NULL

Cell	NULL
79:189-192	NULL
.	NULL

Pearson	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
J.	NULL
Luka	NULL
,	NULL
L.	NULL
Petti	NULL
,	NULL
J	NULL
.	NULL

Sample	NULL
,	NULL
M.	NULL
Birkenbach	NULL
,	NULL
D.	NULL
Braun	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1987	NULL
.	NULL

Identification	NULL
of	NULL
an	NULL
Epstein-Barr	NULL
virus	NULL
early	NULL
gene	NULL
encoding	NULL
a	NULL
second	NULL
component	NULL
of	NULL
the	NULL
restricted	NULL
carly	NULL
antigen	NULL
complex	NULL
.	NULL

Virology	NULL
160	NULL
;	NULL
151-161	NULL
.	NULL

Saksela	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1993	NULL
.	NULL

Negative	NULL
regulation	NULL
of	NULL
immunoglobulin	NULL
kappa	NULL
light-chain	NULL
gene	NULL
transcription	NULL
by	NULL
a	NULL
short	NULL
sequence	NULL
homologous	NULL
to	NULL
the	NULL
murine	NULL
B1	NULL
repetitive	NULL
element	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:3698-3705	NULL
.	NULL

Schlegel	NULL
,	NULL
J.	NULL
,	NULL
I.	NULL
Peters	NULL
,	NULL
S.	NULL
Orrenius	NULL
,	NULL
D.	NULL
K.	NULL
Miller	NULL
,	NULL
N.	NULL
A.	NULL
Thornberry	NULL
,	NULL
T.-T.	NULL
Yamin	NULL
,	NULL
and	NULL
D.	NULL
W.	NULL
Nicholson	NULL
.	NULL

1996	NULL
.	NULL

CPP32/Apopain	NULL
is	NULL
a	NULL
key	NULL
interleukin	NULL
1B	NULL
converting	NULL
enzyme-like	NULL
protease	NULL
involved	NULL
in	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:1841-1844	NULL
.	NULL

Shen	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
T.	NULL
E.	NULL
Shenk	NULL
.	NULL

1995	NULL
.	NULL

Viruses	NULL
and	NULL
apoptosis	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Genet	NULL
.	NULL

Dev	NULL
.	NULL

§105-111	NULL
.	NULL

Shresta	NULL
,	NULL
S.	NULL
,	NULL
D.	NULL
M.	NULL
Maclvor	NULL
,	NULL
J.	NULL
W.	NULL
Heusel	NULL
,	NULL
J.	NULL
H.	NULL
Russell	NULL
,	NULL
and	NULL
T.	NULL
J.	NULL
Ley	NULL
.	NULL

1995	NULL
.	NULL

Natural	NULL
killer	NULL
and	NULL
lymphokine-activated	NULL
killer	NULL
cells	NULL
require	NULL
granzyme	NULL
B	NULL
for	NULL
the	NULL
rapid	NULL
induction	NULL
of	NULL
apoptosis	NULL
in	NULL
susceptible	NULL
target	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:5679-5683	NULL
.	NULL

Smith	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
T.	NULL
Farrah	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Goodwin	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
TNF	NULL
receptor	NULL
superfamily	NULL
of	NULL
cellular	NULL
and	NULL
viral	NULL
proteins	NULL
:	NULL
activation	NULL
,	NULL
costimulation	NULL
and	NULL
death	NULL
.	NULL

Cell	NULL
76:959-962	NULL
.	NULL

Strasser	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
W.	NULL
Harris	NULL
,	NULL
D.	NULL
C.	NULL
S.	NULL
Huang	NULL
,	NULL
P.	NULL
H.	NULL
Krammer	NULL
,	NULL
and	NULL
S.	NULL
Cory	NULL
.	NULL

1995	NULL
.	NULL

Bcl-2	NULL
and	NULL
Fas/APO-1	NULL
regulate	NULL
distinct	NULL
pathways	NULL
to	NULL
lymphocyte	NULL
apoptosis	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:6136-6147	NULL
.	NULL

Strathdee	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
H.	NULL
Gavish	NULL
,	NULL
W.	NULL
R.	NULL
Shannon	NULL
,	NULL
and	NULL
M.	NULL
Buchwald	NULL
.	NULL

1992	NULL
.	NULL

Cloning	NULL
of	NULL
cDNAs	NULL
for	NULL
Fanconi	NULL
's	NULL
anaemia	NULL
by	NULL
functional	NULL
complementation	NULL
.	NULL

Nature	NULL
356:763-767	NULL
.	NULL

Suda	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
S.	NULL
Nagata	NULL
.	NULL

1994	NULL
.	NULL

Purification	NULL
and	NULL
characterization	NULL
of	NULL
the	NULL
fas-ligand	NULL
that	NULL
induces	NULL
apoptosis	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179:873-879	NULL
.	NULL

Sugarman	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
B	NULL
.	NULL

B.	NULL
Aggarwal	NULL
,	NULL
P.	NULL
E.	NULL
Hass	NULL
,	NULL
I.	NULL
S.	NULL
Figari	NULL
,	NULL
M.	NULL
A.	NULL
J.	NULL
Palladino	NULL
,	NULL
and	NULL
H.	NULL
M.	NULL
Shepard	NULL
.	NULL

1985	NULL
.	NULL

Recombinant	NULL
tumor	NULL
necrosis	NULL
factor-	NULL
«	NULL
:	NULL
effects	NULL
on	NULL
proliferation	NULL
of	NULL
normal	NULL
and	NULL
transformed	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

Science	NULL
230:943-945.	NULL
.	NULL

Tarodi	NULL
,	NULL
B.	NULL
,	NULL
T.	NULL
Subramanian	NULL
,	NULL
and	NULL
G.	NULL
Chinnadurai	NULL
.	NULL

1994	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
BHRFI	NULL
protein	NULL
protects	NULL
against	NULL
cell	NULL
death	NULL
induced	NULL
by	NULL
DNA-damaging	NULL
agents	NULL
and	NULL
heterologous	NULL
virus	NULL
infection	NULL
.	NULL

Virology	NULL
201:404-407	NULL
.	NULL

Tartaglia	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
T.	NULL
M.	NULL
Ayers	NULL
,	NULL
G.	NULL
H.	NULL
W.	NULL
Wong	NULL
,	NULL
and	NULL
D.	NULL
V.	NULL
Goeddel	NULL
.	NULL

1993	NULL
.	NULL

A	NULL
novel	NULL
domain	NULL
within	NULL
the	NULL
55	NULL
kd	NULL
TNF	NULL
receptor	NULL
signals	NULL
cell	NULL
death	NULL
.	NULL

Cell	NULL
74:845-853	NULL
.	NULL

Tartaglia	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
R.	NULL
F.	NULL
Weber	NULL
,	NULL
I.	NULL
S.	NULL
Figari	NULL
,	NULL
C.	NULL
Reynolds	NULL
,	NULL
M.	NULL
A.	NULL
Palladino	NULL
,	NULL
and	NULL
D.	NULL
V.	NULL
Goeddel	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
two	NULL
different	NULL
receptors	NULL
for	NULL
tumor	NULL
necrosis	NULL
factor	NULL
voL	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53.	NULL
mediate	NULL
distinct	NULL
cellular	NULL
responses	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:9292-9296	NULL
.	NULL

Tewari	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
V.	NULL
M.	NULL
Dixit	NULL
.	NULL

1995	NULL
.	NULL

Fas-	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor-induced	NULL
apoptosis	NULL
is	NULL
inhibited	NULL
by	NULL
poxvirus	NULL
ern4	NULL
gene	NULL
product	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
:	NULL
3255-3260	NULL
.	NULL

Tewari	NULL
,	NULL
M.	NULL
,	NULL
L.	NULL
T.	NULL
Quan	NULL
,	NULL
K.	NULL
O'Rourke	NULL
,	NULL
S.	NULL
Desnoyers	NULL
,	NULL
Z.	NULL
Zeng	NULL
,	NULL
D.	NULL
R.	NULL
Beidler	NULL
,	NULL
G.	NULL
G.	NULL
Poirier	NULL
,	NULL
G.	NULL
S.	NULL
Salvesen	NULL
,	NULL
and	NULL
V.	NULL
M.	NULL
Dixit	NULL
.	NULL

1995	NULL
.	NULL

Yama/CPP32	NULL
$	NULL
B	NULL
,	NULL
a	NULL
mammalian	NULL
homolog	NULL
of	NULL
CED-3	NULL
,	NULL
is	NULL
a	NULL
crmA-inhibitable	NULL
protease	NULL
that	NULL
cleaves	NULL
the	NULL
death	NULL
substrate	NULL
poly	NULL
(	NULL
ADP-ribose	NULL
)	NULL
polymerase	NULL
.	NULL

Cell	NULL
81:801-809	NULL
.	NULL

Theodorakis	NULL
,	NULL
P.	NULL
,	NULL
C.	NULL
D'Sa-Eipper	NULL
,	NULL
T.	NULL
Subramanian	NULL
,	NULL
and	NULL
G.	NULL
Chinnadurai	NULL
.	NULL

1996	NULL
.	NULL

Unmasking	NULL
of	NULL
a	NULL
proliferation-restraining	NULL
activity	NULL
of	NULL
the	NULL
anti-apoptosis	NULL
gene	NULL
EBV	NULL
BHRFL	NULL
.	NULL

Oncogene	NULL
12:1707-1713	NULL
.	NULL

Thoma	NULL
,	NULL
B.	NULL
,	NULL
M.	NULL
Grell	NULL
,	NULL
K.	NULL
Pfizenmaier	NULL
,	NULL
and	NULL
P.	NULL
Scheurich	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
60-KD	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
receptor	NULL
as	NULL
the	NULL
major	NULL
signal	NULL
trans-ducing	NULL
component	NULL
in	NULL
TNF	NULL
responses	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172:1019-1023	NULL
.	NULL

Thorne	NULL
,	NULL
T.	NULL
E.	NULL
,	NULL
C.	NULL
Voelkel-Johnson	NULL
,	NULL
W.	NULL
M.	NULL
Casey	NULL
,	NULL
L.	NULL
W.	NULL
Parks	NULL
,	NULL
and	NULL
S.	NULL
M.	NULL
Laster	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
cytosolic	NULL
phospholipase	NULL
A	NULL
;	NULL
is	NULL
required	NULL
for	NULL
the	NULL
lysis	NULL
of	NULL
adenovirus-infected	NULL
cells	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:8502-8507	NULL
.	NULL

Trapani	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
K.	NULL
A.	NULL
Browne	NULL
,	NULL
M.	NULL
J.	NULL
Smyth	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Jans	NULL
.	NULL

1996	NULL
.	NULL

Localization	NULL
54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

BHRFI	NULL
AND	NULL
APOPTOSIS	NULL
-	NULL
7517	NULL
of	NULL
granzyme	NULL
B	NULL
in	NULL
the	NULL
nucleus	NULL
(	NULL
a	NULL
putative	NULL
role	NULL
in	NULL
the	NULL
mechanism	NULL
of	NULL
cytotoxic	NULL
lymphocyte-mediated	NULL
apoptosis	NULL
)	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:4127-4133	NULL
.	NULL

Trauth	NULL
,	NULL
B.	NULL
C.	NULL
,	NULL
C.	NULL
Klas	NULL
,	NULL
A.	NULL
M.	NULL
J.	NULL
Peters	NULL
,	NULL
S.	NULL
Matzku	NULL
,	NULL
P.	NULL
Moller	NULL
,	NULL
W.	NULL
Falk	NULL
,	NULL
K.-M.	NULL
Debatin	NULL
,	NULL
and	NULL
P.	NULL
H.	NULL
Krammer	NULL
.	NULL

1989	NULL
.	NULL

Monoclonal	NULL
antibody-mediated	NULL
tumor	NULL
regression	NULL
by	NULL
induction	NULL
of	NULL
apoptosis	NULL
.	NULL

Science	NULL
245:301-305	NULL
.	NULL

Wang	NULL
,	NULL
L.	NULL
,	NULL
M.	NULL
Miura	NULL
,	NULL
L.	NULL
Bergeron	NULL
,	NULL
H.	NULL
Zhu	NULL
,	NULL
and	NULL
J.	NULL
Yuan	NULL
.	NULL

1994	NULL
.	NULL

Ich-7	NULL
,	NULL
an	NULL
Ice/ced-3-related	NULL
gene	NULL
,	NULL
encodes	NULL
both	NULL
positive	NULL
and	NULL
negative	NULL
regulators	NULL
of	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL

Cell	NULL
78:739-750	NULL
.	NULL

White	NULL
,	NULL
E.	NULL
1993	NULL
.	NULL

Regulation	NULL
of	NULL
apoptosis	NULL
by	NULL
the	NULL
transforming	NULL
genes	NULL
of	NULL
the	NULL
DNA	NULL
tumor	NULL
virus	NULL
adenovirus	NULL
.	NULL

Proc	NULL
.	NULL

Soc	NULL
.	NULL

Exp	NULL
.	NULL

Biol	NULL
.	NULL

Med	NULL
.	NULL

204:30-39	NULL
.	NULL

White	NULL
,	NULL
E.	NULL
1996	NULL
.	NULL

Life	NULL
,	NULL
death	NULL
,	NULL
and	NULL
the	NULL
pursuit	NULL
of	NULL
apoptosis	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

10:1-15	NULL
.	NULL

Wissing	NULL
,	NULL
D.	NULL
,	NULL
H.	NULL
Mouritzen	NULL
,	NULL
M.	NULL
Egeblad	NULL
,	NULL
G.	NULL
G.	NULL
Poirier	NULL
,	NULL
and	NULL
M.	NULL
1997	NULL
.	NULL

Involvement	NULL
of	NULL
caspase-dependent	NULL
activation	NULL
of	NULL
cytosolic	NULL
phospholipase	NULL
A2	NULL
in	NULL
tumor	NULL
necrosis	NULL
factor-induced	NULL
apoptosis	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94:5073-5077	NULL
.	NULL

Yuan	NULL
,	NULL
J.	NULL
,	NULL
S.	NULL
Shaham	NULL
,	NULL
S.	NULL
Ledoux	NULL
,	NULL
H.	NULL
M.	NULL
Ellis	NULL
,	NULL
and	NULL
H.	NULL
R.	NULL
Horvitz	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
C.	NULL
elegans	NULL
cell	NULL
death	NULL
gene	NULL
ced-3	NULL
encodes	NULL
a	NULL
protein	NULL
similar	NULL
to	NULL
mammalian	NULL
interleukin-18-converting	NULL
enzyme	NULL
.	NULL

Cell	NULL
75:641-652	NULL
.	NULL

